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To compare the effect of pre-emptive administration of sustained-release (SR) ibuprofen 1.6g 
and etoricoxib 120mg on pain, swelling, trismus, and the quality of life following impacted 




In this single-centre, double-blinded randomised control trial, participants were randomly 
assigned to receive oral SR ibuprofen 1.6g or etoricoxib 120mg 2 hours before third molar 
surgery. In the first 48-hour postoperative period, participants rated their pain intensity every 3 
hours, while awake, and recorded their use of rescue analgesia. A preoperative and 48-hour 
time point measurements were taken for facial swelling, trismus, and the quality of life. The 
postoperative facial swelling was determined by the volumetric differences between the pre- 
and postoperative 3D photographs of the participants, using the 3dMDtrio system (3dMD, 
Atlanta, GA). Trismus was assessed indirectly, by measuring the pre- and postoperative 
interincisal distances at the maximum mouth opening. The quality of life was assessed using 
the short-form Oral Health Impact Profile (OHIP-14). Categorical data of the two study groups 
were compared using Chi-square tests. Clinical characteristics were compared and tested for 
statistical significance using Analysis of variance. A P value of less than 0.05 (P<0.05) was 




Study sample included 135 participants: SR ibuprofen (n=68) and etoricoxib (n=67). Despite 
observing an overall slightly higher pain level in the SR ibuprofen group than the etoricoxib 
group throughout the study period, the difference was not statistically significant. Just over 50% 
of participants in both groups required rescue analgesia (p=0.78), while the mean time to first 
rescue analgesia was 5 hours postoperatively (p=0.66). The total number of rescue analgesics 
consumed was comparable between the two groups (p=0.14). There were no significant 
differences between the two groups in facial swelling (p=0.80), trismus (p=0.86), and the mean 






With no significant differences observed between the performance of the two drugs in acute 
postoperative sequelae, pre-emptive administration of the more economical SR ibuprofen could 
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Third molars are the most commonly impacted teeth in the oral cavity, with an estimated global 
impaction prevalence of 24% (Carter & Worthington, 2016). Approximately 12% of impacted 
third molars are associated with pathology—including dental caries, periodontal disease, 
pericoronitis, root resorption of the adjacent teeth, cysts, and tumours—which justifies their 
surgical removal (Campbell, 2013; Friedman, 2007; Haug et al., 2005). Other reasons 
supporting prophylactic removal of impacted third molars include: (1) planned orthognathic 
surgery; (2) orthodontic treatment; (3) prosthetic rehabilitation; (4) preparation for chemo-
radiotherapy, immunomodifier or bisphosphonate therapies; and (5) joining the military (Hyam, 
2018). A large proportion of patients undergoing third molar extractions are otherwise healthy 
young adults, aged between 20 to 29 years (Coulthard et al., 2014; Friedman, 2007; Haug et al., 
2005). 
 
Mandibular third molars are more frequently impacted than maxillary third molars (Carter & 
Worthington, 2016). Surgery to remove an impacted third molar often necessitates raising a 
full-thickness mucoperiosteal flap. The nature of the impaction may necessitate bone removal 
and tooth sectioning. Like many other operative procedures, third molar surgery is invasive and 
is not free of risks and potential complications. Acute pain, facial swelling, and restricted mouth 
opening (trismus) are transient but inevitable postoperative sequelae after third molar surgery 
(Coulthard et al., 2014; de Santana-Santos et al., 2013; He et al., 2015; Markiewicz et al., 2008). 
A large prospective cohort study involving 8,700 third molar extractions in over 4,000 
participants revealed an overall postoperative complication rate of 16% (Chuang et al., 2007). 
 
A large proportion of patients experience moderate-to-severe pain following impacted 
mandibular third molar surgery which, together with swelling and trismus, accounts for the 
sudden deterioration in their overall well-being and quality of life (Duarte-Rodrigues et al., 
2018). Surgery-mediated tissue injury and inflammation sensitise peripheral nociceptors which 
clinically manifests as pain hypersensitivity (Basbaum et al., 2009). This acute pain, if poorly 
managed, has the potential to induce central sensitisation. This important neurophysiological 
process provides the basis for using pre-emptive analgesia, a pharmacologic strategy involving 
the administration of an analgesic agent before surgery to suppress noxious stimuli arising 
perioperatively to alleviate acute postoperative pain and inhibit the establishment of persistent 





Ibuprofen, including its sustained-release formulation, is arguably the most commonly used 
non-steroidal anti-inflammatory drug (NSAID). It is inexpensive and is readily accessible as an 
over-the-counter medication in most countries (Derry et al., 2009). Ibuprofen ranks as the sixth 
most prescribed medication in New Zealand (Pharmaceutical Management Agency, 2019), and 
over seven million packs were sold over the counter in the United Kingdom in the early 2000s 
(Sheen et al., 2002). Its well-established analgesic property is also reflected by the fact that 
many international clinical trials use ibuprofen as a benchmark to investigate the efficacy of 
novel analgesics (Moore et al., 2015b). Despite its established efficacy, long-term use of 
ibuprofen is implicated in gastrointestinal adverse events, and this prompted the emergence of 
selective cyclooxygenase-2 (COX-2) inhibitors (Hawkey, 2001). Etoricoxib, a second-
generation COX-2 inhibitor effective in the management of moderate-to-severe pain, is claimed 
to have a better gastrointestinal safety profile (Laine et al., 2007). The analgesic efficacy of a 
single dose etoricoxib 120mg is reported to be comparable to, if not better than, a 400mg single 
dose of ibuprofen (Clarke et al., 2014). Unlike ibuprofen, etoricoxib is available by prescription 
only and globally, it is more expensive than the traditional, non-selective NSAIDs (Clarke et 
al., 2014; Doshi et al., 2004; Merck Sharp & Dohme (NZ), 2017). The cost of etoricoxib per 
item in the United Kingdom (£19.75) is twice as higher than sustained-release (SR) ibuprofen 
(£8.06) (The National Health Service, 2014). 
 
Single-dose of oral SR ibuprofen 1.6g and etoricoxib 120mg have a prolonged duration of pain 
blockade, enabling once-daily dosing (Agrawal, Porras, et al., 2003; Baumgartner et al., 1996). 
The pre-emptive analgesic efficacy of etoricoxib and conventional short-acting ibuprofen in 
third molar surgery has been reported (Cetira Filho et al., 2020). However, there is insufficient 
knowledge on how the pre-emptive use of a long-acting SR ibuprofen compares to etoricoxib, 
or any other COX-2 inhibitors, in managing the acute postoperative outcomes after third molar 
surgery. If SR ibuprofen shows equal or better efficacy, then its preferential use as routine pre-
emptive analgesia may be more cost-effective than the more expensive etoricoxib. This would 





2 Literature review 
 
This chapter is subdivided into three sections. First, an overview of pain, swelling, and trismus 
will be provided, followed by the impact of third molar surgery on a patient’s quality of life. 
Second, pharmacological agents relevant to this thesis will be reviewed. Finally, the current 
understanding of pre-emptive analgesia, along with a critical appraisal of the literature 
addressing its impact in third molar surgery will be presented. The term, ‘third molar surgery’ 
used in this thesis, refers to the surgical removal of third molars. 
 
 Third molar surgery outcomes 
 
Pain, facial swelling, and restricted mouth opening (trismus) are expected acute postoperative 
sequelae of third molar surgery (Coulthard et al., 2014; de Santana-Santos et al., 2013; He et 
al., 2015; Markiewicz et al., 2008). Although transient in nature, they are responsible for an 
immediate and significant deterioration in the quality of life of many patients. Therefore, much 
interest has been concentrated on developing various methods and protocols to mitigate 
morbidity associated with these common postoperative outcomes. Since this thesis focuses on 
pain, swelling, and trismus after third molar surgery, it is paramount to have an in-depth 




This section will begin with the definition of pain and a review of its neurophysiology. Risk 
factors influencing the level of pain after third molar surgery and the measures to manage pain 
will be discussed. Lastly, various instruments used to evaluate pain will be explored. 
 
2.1.1.1 Definition of pain 
 
Pain is defined as “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” (International Association for 
the Study of Pain, 2017). Pain is a multidimensional sensory experience resulting from complex 
interactions between physiological, emotional, and cognitive factors (Woolf, 2004). 
 
Pain is a protective physiological mechanism that defends an individual against painful, tissue-




behavioural response that alerts the individual to recognise and avoid such stimuli (Latremoliere 
& Woolf, 2009). Although this protective system can be further strengthened through 
sensitisation of the pain transmission circuit, it may become persistent and maladaptive. Such 
transition from physiological to pathological pain processing is no longer useful and forms the 
basis for a various ‘medically unexplained’ chronic psychosomatic or somatoform pain 
syndromes, such as fibromyalgia, headache, complex regional pain syndrome, and 
temporomandibular dysfunction (Latremoliere & Woolf, 2009; Woolf, 2011). 
 
2.1.1.2 Anatomy and neurophysiology of orofacial pain 
 
The nociceptive system is responsible for the sensory recognition of pain evoked by a damaging 
or potentially damaging stimulus. This system comprises nociceptors, a key subpopulation of 
specialised, high-threshold sensory neurons that extends from the periphery to the brain via the 
spinal cord, brainstem, and thalamus (Woolf, 2004). In the orofacial area, the cell bodies of 
trigeminal primary nociceptive fibres are found within the trigeminal ganglion and their 
peripheral axons are distributed in various orofacial structures, including orofacial skin and 
muscles, oral mucous membrane, tooth pulp, gingiva, tongue, and temporomandibular joints 
(Iwata et al., 2019). A central axon projects from the cell body to synapse with second-order 
neurons in the central nervous system (CNS) (Basbaum et al., 2009) (Figure 1). Nociceptors 
are high-threshold sensory neurons that are preferentially excitable to stimuli only within the 
‘painful’ range (Basbaum et al., 2009). They are subdivided into thinly myelinated Aδ fibres 
(transmit fast-sharp, well-localised ‘first’ pain) and unmyelinated C fibres (transmit poorly 









Nociception is initiated by the conversion of noxious stimuli into receptor potentials at the 
peripheral terminal endings of primary nociceptors. The subsequent activation of various 
voltage-gated ion channels generates action potentials that relay noxious information along the 
central trigeminal fibres to synapse with second-order neurons in the trigeminal spinal 
subnucleus caudalis and upper cervical spinal cord (Iwata et al., 2019). The second-order 
neurons are arranged within anatomically and electrophysiologically distinct laminae of the 
dorsal horn of the spinal cord (Figure 2). These spinal second-order neurons can be stratified 
into three subtypes: (1) nociceptive-specific neurons that process noxious signals conducted via 
Aδ and C fibres; (2) neurons that detect innocuous mechanical stimuli (for example, light touch) 
carried via Aβ fibres; and (3) wide-dynamic-range neurons that receive both innocuous and 






A plethora of neurotransmitters, including glutamate, substance P, and calcitonin gene-related 
peptides (CGRP), excite second-order relay neurons. These neurons ascend to engage the 
somatosensory cortex via the ventral posteromedial thalamic nucleus to enable localisation and 
perception of the intensity of the noxious stimuli (that is, sensory-discriminative characteristics 
of pain). Some of the nociceptive signals are relayed to the limbic system that addresses the 
emotional components of pain (Basbaum et al., 2009; Iwata et al., 2019). 
 
The afferent nociceptive signals are regulated by descending modulatory systems arising from 
various supraspinal sites, predominantly from the brainstem. The alterations in the balance 
between facilitation and inhibition are dynamic and dependent on the pathological, behavioural, 
and emotional contexts of the individual. The imbalance between the positive and negative 
modulation is suggested to be responsible for the conversion of acute pain to chronic pain 
(Heinricher et al., 2009; Iwata et al., 2019). It is clear that the anatomical motif of a ‘hard-wired’ 
nociceptive pathway is no longer valid. Instead, nociceptive circuits are dynamic at various 
levels and exhibit extreme malleability to repeated and intense stimuli, inflammation, and 
neural injury (Latremoliere & Woolf, 2009). Such neural plasticity involves altered chemical 
profile, structure, and function (Woolf & Salter, 2000) and forms the fundamental basis of 
peripheral and central sensitisation. 
 
Figure 2. Connections between primary afferent fibres and second-order neurons in the spinal 








Upon tissue damage and inflammation, peripheral terminals of nociceptors and inflammatory 
cells release a myriad of algogenic substances that contribute to the so-called ‘inflammatory 
soup’. The pain-promoting mediators that constitute the inflammatory soup are substance P, 
CGRP, glutamate, serotonin, histamine, bradykinin, prostaglandins, cytokines, chemokines, 
and neurotrophins (Basbaum et al., 2009; Woolf, 2004). The altered chemical milieu reduces 
the threshold of peripheral nociceptors distributed in the inflamed tissue wound. This 
phenomenon is called peripheral sensitisation; the net effect is heightened responsiveness to 
stimuli and greater neuronal excitability (Woolf, 2011). It is considered the body’s extra 
defence against noxious stimuli, meaning that the nociceptive system becomes so hyper-alert 
that, whenever it conceives the risk of further tissue damage is likely, it generates aversive 
behavioural responses to avoid such stimuli (Latremoliere & Woolf, 2009). Peripheral 
sensitisation clinically manifests as inflammatory pain hypersensitivity that is bound within the 
site of tissue injury (primary hyperalgesia). It also requires continuous peripheral noxious input 
and/or pathology for its sustenance (Latremoliere & Woolf, 2009; Woolf & Salter, 2000). 
NSAIDs are effective at reducing inflammatory pain associated with peripheral sensitisation 




Central sensitisation is a state of neuronal hyperexcitability in the CNS (Woolf, 1983, 2011). 
Current understanding is that three distinctive mechanisms are responsible: a profound 
enhancement and augmentation in the membrane excitability, synaptic efficacy, or disinhibition. 
Unlike peripheral sensitisation, central sensitisation represents a dysfunctional, hypersensitive 
state with “increased gain of the nociceptive system” (Latremoliere & Woolf, 2009). Such 
change in the functional neuronal properties of the CNS underscores a key distinction that pain 
associated with central sensitisation is no longer defined by the existence of peripheral noxious 
stimuli (Latremoliere & Woolf, 2009; Woolf, 2011). 
 
The threshold, spatial, and temporal changes in pain sensibility specific to central sensitisation 
are explained by: (1) functional engagement of subthreshold sensory inputs transmitted via non-
nociceptive Aβ fibres into the central circuits to generate Aβ fibre-mediated pain (that is, 
allodynia) (Baba et al., 2003; Latremoliere & Woolf, 2009; Woolf & Salter, 2000); (2) 




hyperalgesia); and (4) prolonged post-stimulus hyperalgesia (Latremoliere & Woolf, 2009; 
Woolf, 2011). These neurophysiological changes and subsequent augmentation in the central 
component of the nociceptive system manifest as primary and secondary hyperalgesia and 
allodynia that persist autonomously, independent of the peripheral noxious input (Woolf, 2011). 
Centrally acting drugs, such as ketamine, gabapentinoids, and selective serotonin and 
noradrenaline reuptake inhibitors, are pharmacological agents used to reduce central 
sensitisation (Dahl & Kehlet, 2011; Woolf, 2011). 
 
2.1.1.3 Postoperative pain in third molar surgery 
 
Surgical trauma in third molar surgery (primary phase of injury) initiates the activation of 
trigeminal nociceptive system. The tissue destruction and subsequent inflammation release a 
diverse range of inflammatory and pronociceptive mediators; this marks the secondary phase 
of injury that remains profound during the postoperative period (Kissin, 1996). Intracellular 
contents released from damaged cells—and proinflammatory substances—act directly on 
nociceptors to induce immediate pain. At the same time, they form the ‘inflammatory soup’ 
that sensitises free nerve endings and establish peripheral sensitisation. In short, postoperative 
third molar pain is mostly inflammatory in nature (Seymour & Walton, 1984) and, if poorly 
managed, peripheral sensitisation has the potential to induce central sensitisation (Iwata et al., 
2019; Kehlet et al., 2006). Therefore, the use of aggressive pain relief in the immediate 
postoperative period is justified. 
 
2.1.1.4 Risk factors for postoperative pain 
 
Patient demographic characteristics appear to influence the level of postoperative pain. Review 
of the recent evidence indicates that females are more likely to report severe pain than males. 
It has been suggested that gender differences may be explained by psychosocial factors 
(stereotypic gender roles, mood, coping, catastrophising, depression, anxiety), hormonal factors, 
and endogenous pain modulation affecting females unfavourably (Fillingim et al., 2009). 
Consistent with this finding, females have been shown to have a higher risk for pain than males 
in third molar surgery (Benediktsdóttir et al., 2004; de Santana-Santos et al., 2013). However, 
one study has observed a higher proportion of males than females reporting more pain (Capuzzi 
et al., 1994). Although the investigators did not give an account for such a contradictory finding, 
some unrecognised sociocultural differences could have influenced pain responses in this 




reported (Benediktsdóttir et al., 2004; Renton et al., 2001). Surgery is generally longer among 
older age groups, many of whom require more bone removal and tooth sectioning. Greater age 
has, therefore, been shown to be associated with more pain following third molar surgery 
(Capuzzi et al., 1994; Chuang et al., 2007). Additionally, poor preoperative oral hygiene 
(Larrazábal et al., 2010; Peñarrocha et al., 2001) and pain preceding surgery (Katz et al., 2011) 
are recognised risk factors for greater postoperative pain. 
 
Tooth-related factors, such as root morphology (Benediktsdóttir et al., 2004), the type and depth 
of impaction relative to the ramus (Grossi et al., 2007; Van Gool et al., 1977; Yuasa & Sugiura, 
2004), and acute pericoronal inflammation at the time of surgery (Van Gool et al., 1977) have 
been identified to influence postoperative pain. Moreover, an association between the expertise 
of the surgeon and postoperative pain has been found; that is, the greater the experience of the 
surgeon, the less the postoperative pain (Capuzzi et al., 1994), by virtue of shorter operating 
time, gentler tissue handling (that is, less mechanical trauma), and better patient selection and 
clinical decision-making. Coulthard et al. (2014) found triangular flaps and secondary wound 
closure to be associated with less pain than envelope flaps and primary closure, respectively. 
Other operative risk indicators for greater pain include: (1) surgical removal rather than simple 
extraction of third molars; (2) partially impacted third molars rather than those that are fully 
impacted; (3) longer operative time; (4) tight suturing; and (5) intraoperative exposure of the 
inferior alveolar nerve (Benediktsdóttir et al., 2004; Van Gool et al., 1977). 
 
2.1.1.5 Prevention and management of pain 
 
The use of pharmacological agents remains the cornerstone of pain management following third 
molar surgery. Analgesics may be classified as mild, moderate, or strong according to the World 
Health Organization’s pain relief ladder (Figure 3) (World Health Organization, n.d.). 
According to this three-step model, paracetamol and NSAIDs are considered mild analgesics; 
weak opioids, like codeine, belong to the moderate strength category; and strong opioids, like 
oxycodone and fentanyl, are strong analgesics. In third molar surgery, commonly prescribed 
agents include paracetamol, NSAIDs, and codeine. While these drugs can be taken as 
monotherapy, the intensity of third molar postoperative pain often demands a combined 
analgesic regimen. NSAIDs are arguably one of the most popular analgesics of choice for both 
clinicians and patients alike; their analgesic efficacy against mild-to-moderate postoperative 
pain has been well documented (Moore et al., 2015b). NSAIDs are the principal interventional 




in Section 2.2. Opioids are centrally acting agents with the well-documented adverse effects of 
nausea, vomiting, constipation, sedation, and respiratory depression. A Cochrane systematic 
review examining 35 clinical trials concluded that codeine, when used alone, is inferior to non-
opioid analgesics, such as paracetamol 1g, ibuprofen 400mg, and naproxen 500mg (Derry et 
al., 2010). Its poor performance as a single agent means that codeine is often prescribed 
alongside non-opioids. However, a recent clinical trial demonstrated an efficacy of combined 
paracetamol, ibuprofen, and codeine which was equivalent to that without codeine (Best et al., 
2017). The relative inefficacy of codeine in some populations is explained by certain genetic 
variants of the CYP2D6 enzyme that lead to the poor metabolism of codeine into its active 
compound, morphine (Smith, 2009). It is known that about 10% of Caucasians lack CYP2D6 
activity, and that they clinically present as poor metabolisers of codeine (Cascorbi, 2003). Also, 
higher doses are often restricted due to its undesirable side-effects and the risk of tolerance and 
dependency (Derry et al., 2010). Despite available evidence indicating more harm than benefits, 
routine prescription of codeine remains frequent in oral surgery. It appears to be based on the 
clinician’s experience and preference, as well as patients’ tolerability. In summary, 
management of third molar postoperative pain continues to rely on polytherapy, utilising 
combinations of various non-opioids and codeine. Another avenue for reducing postoperative 
pain is the concept pre-emptive analgesia. This is the key matter in this thesis and will be 
reviewed separately in Section 2.3. 
 







2.1.1.6 Measuring pain 
 
Pain is a complex somatic sensation that is multidimensional in nature and incorporates 
emotional and affective elements (Woolf, 2004). Accordingly, the intensity of pain does not 
always correspond to the magnitude of tissue damage, and each individual’s pain perception 
and responses are highly variable. In addition, the subjective disposition of pain makes it 
difficult, if not impossible, to accurately measure the pain experience (Leach & Davenport, 
2018). It is critical to gauge pain correctly in the perioperative setting, not only from the 
diagnostic standpoint, but to monitor disease/healing progress, guide treatment, and evaluate 
the effectiveness of a particular treatment delivered. It is also important from the research 
perspective. Evaluating pain involves measurements of acute or chronic pain and can be either 
uni- or multidimensional (Bendinger & Plunkett, 2016). 
 
The visual analogue scale (VAS), numeric rating scale (NRS), verbal rating scale (VRS), and 
faces pain scale are classic examples of patient-reported single-item scales to evaluate pain 
intensity. They are easily administered, reliable and valid tools used most frequently in acute 
pain settings. While the VAS, NRS, and VRS are solely concerned with pain intensity, the 
McGill Pain Questionnaire (MPQ) and Brief Pain Inventory (BPI) are multi-tiered; they 
encompass questions relating to sensory, affective, cognitive-evaluative, and functional 
elements of pain (Bendinger & Plunkett, 2016). 
 
Since unidimensional instruments disregard the multifaceted phenomenon of pain, there are 
concerns that perioperative care may not approximate patients’ needs and so possibly render 
either under- or overtreatment (van Boekel et al., 2017; Younger et al., 2009). Some advocate 
adopting a multidimensional assessment tool in perioperative care to help overcome this 
problem (van Boekel et al., 2017). However, its comprehensive detail and complexity is time-
consuming in busy clinics and somewhat tedious for patients, research participants, and 
clinicians. Thus, unidimensional instruments remain more practical and simple, and are easily 
understood by patients (Bendinger & Plunkett, 2016; Younger et al., 2009). 
 
The VAS is considered the gold standard (Bendinger & Plunkett, 2016) and features 
predominantly in clinical pain research, including third molar studies. It comprises a 100mm-
long horizontal line bounded by a pole at each extreme of the line. The left end of the extreme 




specific training; participants are to score their pain by placing a line perpendicular along the 
scale that best matches the individual’s pain experience. VAS is highly sensitive and does not 
rely on one’s verbal or reading skills. However, it cannot be administered via a remote interview 
and requires the patient’s capacity to translate pain severity to an abstract scale. This may be 
challenging in young children, older people, and patients with intellectual disability (Kliger et 
al., 2015). 
 
The VRS, also known as a Likert scale, is an ordinal scale that comprises five ascending 
descriptors of pain, from “no pain” to “excruciating pain and agony”. This scale is favoured for 
those who have difficulty expressing their pain intensity into a numerical value. Unlike the 
VAS, the categorical nature of the VRS invariably diminishes its precision in detecting the fine 
differences in pain intensity. Furthermore, its use may be unfavourable for those experiencing 
a language barrier (Bendinger & Plunkett, 2016; Kliger et al., 2015). 
 
The limitations associated with these surrogate measures of pain have generated growing 
interest in the development of objective markers of pain. Skin conductance and heart rate have 
been investigated, but these physiologic variables are directly under the influence of many 
surgical and medical interventions and other factors that influence the autonomic nervous 
system. Neuroimaging, such as functional magnetic resonance imaging, 
magnetoencephalography, and positron emission tomography, have been studied. However, 
none of these approaches are deemed adequate to objectively differentiate and quantify pain 
(Younger et al., 2009). Accordingly, self-reported pain measures continue to remain invaluable 




This section will review the definition of swelling and its pathophysiology. Factors influencing 
greater postoperative swelling after third molar surgery will be highlighted, followed by the 
contemporary practice to minimise and manage swelling. Lastly, methods used to measure 







2.1.2.1 Definition of swelling 
 
Oedema is defined as “a palpable swelling produced by expansion of the interstitial fluid 
volume” (Sterns, 2020). In the context of postsurgical oedema, swelling represents one of the 
cardinal signs or symptoms of inflammation: pain, swelling, heat, redness, and loss of function 
(Kumar et al., 2018). 
 
2.1.2.2 Pathophysiology of postoperative swelling 
 
Any insult to the tissue, whether it is physical or infectious, triggers an acute inflammatory 
response. The three distinctive morphological attributes of acute inflammation are vasodilation, 
exudation of protein-rich fluid, and neutrophilic infiltration. Upon injury, various chemical 
mediators (including histamine, bradykinin, leukotrienes, and prostaglandins) elicit 
vasodilation and increase vascular permeability. Changes in the local haemodynamics facilitate 
leakage of an exudate into the interstitial compartment, and the resultant accumulation of excess 
fluid clinically manifests as oedema. Increased vascular permeability can also arise from direct 
injury to the endothelium that leads to endothelial cell necrosis and detachment. Eventually, 
oedema resolves by resorption of excess fluid via the lymphatic system (Kumar et al., 2018). 
Facial swelling peaks around 48 hours following third molar surgery and usually resolves by 
the seventh day as the healing progresses (Hupp et al., 2018). 
 
2.1.2.3 Risk factors for postoperative swelling 
 
The severity of postsurgical oedema is tissue-dependent and directly proportional to the 
magnitude of tissue injury (Hupp et al., 2018). Oedema tends to develop more readily in tissues 
with abundant loose connective tissue. The orofacial tissues in the vicinity of third molars have 
a substantial amount of loose connective tissue and are richly vascularised; these structural 
features make the third molar region susceptible to significant postoperative facial swelling 
(Laureano Filho et al., 2008). Male gender (Pérez-González et al., 2018; Yuasa & Sugiura, 
2004), older age (Yuasa & Sugiura, 2004), and high body mass index (Pérez-González et al., 
2018) have shown to influence facial swelling after third molar surgery. The greater depth of 
impaction (Berge & Bøe, 1994; Yuasa & Sugiura, 2004), spatial relationship of the third molar 
with lingual and buccal cortices (Pérez-González et al., 2018), surgery involving reflection of 
the mucoperiosteal flap (Hupp et al., 2018; Van Gool et al., 1977), and longer operative time 




are well-known determinants of greater swelling. Specific surgical techniques implicated in less 
swelling include triangular flaps, secondary wound closure, and the use of surgical drains 
(Coulthard et al., 2014). 
 
2.1.2.4 Prevention and management of swelling 
 
The surgical factors influencing greater swelling after third molar surgery have been reviewed 
in Section 2.1.2.3. The perioperative use of glucocorticoids is a well-established practice in oral 
and maxillofacial surgery owing to their superior effect in postoperative inflammatory oedema 
management (Almeida et al., 2019; Becker, 2013; Dan et al., 2010; Markiewicz et al., 2008). 
Glucocorticoids are both anti-inflammatory and immunosuppressive. Their therapeutic effects 
are exerted primarily via the genomic mechanism (Becker, 2013). This time-consuming process 
involves the binding of the glucocorticoid with the cytosolic glucocorticoid receptor found in 
virtually all cells. The receptor-steroid complex then migrates to bind to the nucleic acid and 
interferes with the genetic synthesis of enzymes that regulate arachidonic acid metabolism and 
cellular functions. Consequently, glucocorticoids reduce the synthesis and/or release of 
proinflammatory mediators (such as prostaglandins and immune-related cytokines) that induce 
the vascular changes and leukocytic functional changes evident in acute inflammation (Becker, 
2013). These, in turn, translate into suppression of inflammation and both innate and cellular 
immunity. 
 
The literature recommends a single dose of a corticosteroid to be administered before third 
molar surgery because it achieves better control of swelling. That agent should have a half-life 
which is long enough to cover the acute postoperative phase during which the swelling is 
anticipated to peak (Almeida et al., 2019; Becker, 2013). Dexamethasone and 
methylprednisolone have shown to be superior to other types of corticosteroids (Almeida et al., 
2019). Corticosteroids can be administered orally, intravenously, intramuscularly or 
submucosally, but there is no convincing evidence to suggest that any route is better than the 
others in preventing swelling (Almeida et al., 2019). There is no consensus on the best dose, 
and this is highly variable depending on the potency of the drug used (Almeida et al., 2019). 
 
Non-pharmacological approaches used to manage postoperative swelling include cryotherapy 
and low-level laser therapy. Despite cryotherapy being a long-established method for 
minimising pain, swelling, and discomfort, its use is largely empirical and the true effectiveness 




therapeutic effect is based on the understanding that cooling reduces the inflammatory response 
and muscle spasm, evoking vasoconstriction and cold-induced neuropraxia by reducing 
conduction velocity along sensory fibres. However, its prolonged application can induce cold 
burns, microvascular ischaemia or local tissue necrosis, and impede lymphatic drainage 
(Meeusen & Lievens, 1986). Moreover, anatomical variations in tissue thickness may also 
influence the efficacy of cryotherapy (Gelesko et al., 2011). Cryotherapy can range from simply 
using icepacks or frozen gel packs to hilotherapy, a sophisticated facial mask with a channel of 
circulating cooled water (Do Nascimento-Júnior et al., 2019). Hilotherapy has gained much 
attention since its introduction. Its prime advantage is that the device is adjustable to the desired 
temperature that is then stably maintained to deliver standardised cryotherapy without the 
temperature variations inherent in icepacks. Moreover, the specially contoured facial mask 
covers a greater surface area than the standard application of icepacks (Glass et al., 2016). 
However, a recent meta-analysis concluded that cryotherapy has no benefit in reducing swelling 
and trismus after third molar surgery and yields only a small moderation in pain (Do 
Nascimento-Júnior et al., 2019). 
 
Low-level laser therapy (LLLT) is an alternative non-pharmacological modality used to reduce 
postoperative swelling. LLLT promotes lymphatic regeneration and decreases vascular 
permeability that ultimately facilitates the resorption of excess interstitial fluid (Landucci et al., 
2016). Although there have been plenty of randomised control trials investigating the effects of 
LLLT in third molar surgery, poor methods, designs, and reporting standards have 
compromised the validity of evidence and rendered conflicting findings in the systematic 
reviews (Brignardello-Petersen et al., 2012; Dawdy et al., 2017; He et al., 2015). Nevertheless, 
the consensus is that LLLT offers no tangible benefit in reducing pain, swelling or trismus, and 
its routine use is not endorsed in third molar surgery (Dawdy et al., 2017). 
 
Attempts have been made to create an artificial intelligence (AI) model to predict facial swelling 
after third molar surgery (Pereira & Sinha, 2020). The network input parameters in an AI model 
developed by Zhang et al. (2018) consisted of the following: (1) patient factors (age, gender, 
physique, oral hygiene); (2) tooth-related factors (the depth of third molar impaction, the 
number of roots); and (3) surgical factors (incision type, location and quantity of bone removal, 
sectioning of teeth, fracture of the root and/or lingual bone, operative time). The investigators 
showed that this artificial neural network had 98% accuracy in predicting the severity of facial 
swelling following third molar extraction. Currently, there is no model universally accepted to 




based on the surgeon’s personal experience. Although the application of AI has yet to be 
welcomed in oral and maxillofacial surgery (Pereira & Sinha, 2020), further development of 
this innovative approach may prove useful in predicting and aiding specific perioperative care 
plans for patients in order to minimise acute inflammatory outcomes after surgery. 
2.1.2.5 Swelling measurement 
 
In oral and maxillofacial surgery, facial swelling can be determined via a multitude of 
techniques: (1) traditional ‘hands-on’ anthropometry using calipers or metric tapes to measure 
the distances between defined facial landmarks; (2) facebow; (3) cephalostat; (4) visual 
inspection (that is, VAS); (5) laser scanning; (6) imaging modalities, such as computed 
tomography, ultrasound, and magnetic resonance imaging; and (7) stereophotogrammetry 
(Aldridge et al., 2005; Coulthard et al., 2014; Esen et al., 1999; Kau et al., 2007). 
 
Traditional anthropometry is a direct method that is still widely used to quantify postoperative 
swelling in third molar surgery. The typical facial landmarks used are the gonion, tragus, ala of 
the nose, pogonion, labial commissure, and lateral canthus of the eye (Albuquerque et al., 2017; 
Costa et al., 2015). Its popularity is credited to its convenience; it is simple to implement and is 
inexpensive (Pérez-González et al., 2018). However, this conventional method is time-
consuming in that each measurement can only be taken individually and therefore, far from 
ideal if the participants are young children or those with special needs. Further, direct 
measurement means that it demands close physical contact with the participant, and skin 
deformation resulting from manual pressure during contact is inevitable, thereby producing 
error (Aldridge et al., 2005). 
 
The complex three-dimensional (3D) structures of the face and the associated soft tissue forms 
are difficult to measure accurately (Lübbers et al., 2010; White et al., 2020). This has led to the 
advancement of 3D stereophotogrammetric imaging systems. The 3dMDtrio system (3dMD, 
Atlanta, GA) employs both stereophotogrammetry and the structured light technique. The 
system projects a ‘structured’ light pattern onto a facial surface, and the subsequent distortion 
of the light pattern is captured with multiple synchronised cameras configured as a stereopair. 
The captured information is then translated into the 3D coordinates of facial surface to 
reconstruct a 3D image (Aldridge et al., 2005; Kau et al., 2007). This indirect 3D 
anthropometric measurement introduces many advantages in healthcare and research: (1) ultra-
fast capture speed of 1.5 milliseconds overcomes large motion errors; (2) non-invasive, 




review of the images; (4) it creates image archives for future needs; (5) proven reliability of 
data acquisition, anatomic precision, and repeatability; and (6) manipulation and analysis of 
images in 3D space (Aldridge et al., 2005; Heike et al., 2010; White et al., 2020). Its drawbacks 
include: (1) shadows cast by hair or clothing that may interfere with image analysis; (2) 
landmarks that are identified only by direct palpation; and (3) limitation to external surface 
morphology, meaning that intraoral data are excluded (Aldridge et al., 2005). However, the 
benefits of indirect 3D stereophotogrammetry are said to far exceed their limitations (Aldridge 
et al., 2005). Thus, it is now becoming the preferred device for the detailed assessment of 
dysmorphology, aiding diagnosis, and facilitating treatment planning and comprehensive 




This section will review the definition of trismus and its pathophysiology in third molar surgery. 
Risk factors and measures to prevent and manage trismus will also be highlighted. 
 
2.1.3.1 Defining trismus 
 
Trismus is defined as “a motor disturbance of the trigeminal nerve, especially spasm of the 
masticatory muscles, with difficulty in opening the mouth” (Dorland, 2012). However, this 
diagnostic term has been used loosely in the literature to represent a restricted mouth opening 
regardless of its aetiology (Tveterås & Kristensen, 1986). 
 
Trismus, or limited mouth opening, is an anticipated postoperative sequela following 
mandibular third molar surgery. Patients tend to experience difficulty in normal functioning, 
such as eating and talking, and limited jaw movement may take at least over a week to resolve. 
Despite this inconvenience, trismus is believed to be protective in the early postoperative period; 
by restricting the jaw movement, it is effectively ‘immobilising’ the mandible, thereby allowing 
the patient to rest the jaw to promote healing (Coulthard et al., 2014). 
 
2.1.3.2 Pathophysiology of trismus in third molar surgery 
 
Trauma-induced inflammation of the masticatory muscles is largely responsible for trismus 
after third molar surgery (Coulthard et al., 2014; Ernberg et al., 2007; Hupp et al., 2018). It is 




the masticatory muscles, leading to trismus. Another neurogenic explanation is that 
inflammation-mediated release of pain mediators sensitises the nociceptors and modulates the 
motor function; this means that the resultant reflex trismus serves as a protective mechanism 
(Ernberg et al., 2007; Tveterås & Kristensen, 1986). Direct surgical trauma to masticatory 
muscles can result from stripping of the temporalis tendon during flap elevation or from a 
trauma-induced haematoma. The medial pterygoid can also be damaged during the mandibular 
nerve block procedure if the needle penetrates the muscle or by chemical irritation from the 
local anaesthetic agent. Excessive and negligent flap retraction can tear the periosteum and 
damage the overlying muscle. The pain following muscle damage stimulates ‘muscle guarding’, 
a pain reflex that initiates spasmodic contraction of the affected muscle and compromises free 
movement of the mandible (Balakrishnan et al., 2017; Hupp et al., 2018; Tveterås & Kristensen, 
1986). 
 
2.1.3.3 Risk factors, prevention, and management of trismus 
 
Female gender, older age, and deep impaction have been reported as predictors of trismus (de 
Santana-Santos et al., 2013; Grossi et al., 2007). With surgical techniques, the use of a surgical 
drain has been shown to improve mouth opening, while different flap designs and wound 
closure techniques have shown equivocal results (Coulthard et al., 2014). Other operative 
variables favouring trismus include bone removal and tooth sectioning, longer operative time, 
and having a less-experienced surgeon (de Santana-Santos et al., 2013; Grossi et al., 2007). 
 
Systematic reviews and meta-analyses have confirmed the benefit of preoperative 
administration of corticosteroids for controlling trismus (Almeida et al., 2019; Markiewicz et 
al., 2008). By contrast, cryotherapy and LLLT have shown no apparent improvement in trismus 
following third molar surgery (Dawdy et al., 2017; Do Nascimento-Júnior et al., 2019). 
 
2.1.3.4 Trismus measurement 
 
Trismus is assessed indirectly, by using a caliper or ruler to measure the maximal interincisal 
distance between the maxillary and mandibular incisors on mouth opening (Coulthard et al., 






 Measuring oral-health-related quality of life 
 
A paradigm shift occurred in the late 20th century in the definition of health, which advanced 
from its traditional description as the absence of disease, to the contemporary definition of 
optimal functioning and social and psychological well-being (Locker, 1988). Therefore, this 
conceptual evolution of health has extended to embrace the quality of life as an important health 
outcome (Slade, 1997). 
 
In dentistry, the Oral Health Impact Profile (OHIP) is the most universally recognised 
instrument “to measure people’s perceptions of the impact of oral conditions on their well-
being” (Slade, 1997). It consists of 49 questions based on Locker's model of oral health 
concerned with pain/discomfort, functional limitation, impairment, disability, and handicap 
(Locker, 1988). OHIP confers comprehensiveness to data, but the large-scale instrument is 
time-intensive and not practical in certain clinical settings. The demand for a more pragmatic 
approach to measurement has led to the development of the shortened OHIP-14. It has 
acceptable reliability and validity, and so it has been used routinely in many epidemiological 
studies and clinical trials (Slade, 1997; Slade et al., 2004). 
 
2.1.4.1 Impact of third molar surgery on quality of life 
 
Pain, discomfort, swelling, and trismus are predictable short-term postoperative morbidities 
inseparable from third molar surgery (Bienstock et al., 2011). Notwithstanding that these 
outcomes are expectations for many, they are associated with significant personal costs. Since 
the majority of third molar operations are elective, patients naturally demand detailed 
information, specifically on its negative impact on daily activities, occupational burden, and 
anticipated recovery period (Bienstock et al., 2011; Shugars et al., 2006). Understanding the 
postoperative course of third molar surgery and its impact on patients’ quality of life is essential 
for both patients and clinicians, for several reasons. Patients may depend on this information to 
optimise surgical scheduling to minimise disruption to their working and social lives (Bienstock 
et al., 2011). For clinicians, it allows reviewing the perioperative management plan and 
identifying any factors that may prolong the duration of postoperative disability. It also helps 
clinicians to provide appropriate advice to patients and engender realistic expectations about 






Age, female gender, certain anatomic features (complete-bony impaction, mandibular third 
molar removal, number of third molars removed, the degree of surgical difficulty), surgical 
duration, the amount of analgesic consumption, and perioperative complications have been 
proposed as variables associated with poorer postoperative quality of life (Bienstock et al., 2011; 
Negreiros et al., 2012; Sato et al., 2009; van Wijk et al., 2009). Delayed healing after surgery 
has also been shown to delay a return to a normal lifestyle (Ruvo et al., 2005). 
 
The quality of life has been shown to worsen typically over the first five postoperative days, 
followed by a remarkable improvement by around one week after surgery (Bienstock et al., 
2011; Colorado-Bonnin et al., 2006; Deepti et al., 2009; Duarte-Rodrigues et al., 2018; Mcgrath 
et al., 2003; Shugars et al., 2006). That adverse impact is apparent across all dimensions of 
quality of life. Physical pain, functional limitations, and physical disability are the most 
frequently affected domains in the postoperative period. Additionally, many patients experience 
some form of psychological and social ill-being, in the form of feeling tense, difficulty relaxing, 
or becoming increasingly self-conscious (Duarte-Rodrigues et al., 2018; Mcgrath et al., 2003; 
Shugars et al., 2006). 
 
Postoperative pain has been identified as accounting for the sudden deterioration in life quality 
following third molar surgery. A very high proportion of patients complain of pain and 
difficulty when eating and talking immediately after surgery (Duarte-Rodrigues et al., 2018; 
Mcgrath et al., 2003; van Wijk et al., 2009). Many published series indicate pain resolving 
progressively over seven days following surgery, and improvement in the quality of life 
reflecting the downward trend in the level of pain (Colorado-Bonnin et al., 2006; Duarte-
Rodrigues et al., 2018; White et al., 2003). Although it is generally expected that, by seven days 
post-surgery, patients have recovered enough to resume their usual lifestyle, some may still 
experience impaired quality of life. The reported average duration of postoperative disability 
(described as days of normal daily activity curtailed, or discontinued work) is two to three days 
(Bienstock et al., 2011; Colorado-Bonnin et al., 2006; Haug et al., 2005; White et al., 2003), 





 The use of NSAIDs in third molar surgery 
 
This section will outline the mechanism of action of NSAIDs and its associated adverse effects. 
The pharmacology of sustained-release ibuprofen and etoricoxib will also be reviewed. 
 
 Inflammation as a response to injury and the action of NSAIDs 
 
Acute inflammation is a rapid innate response of short duration that aims to abolish injurious 
substances and promote tissue healing. Intricate interactions among inflammatory mediators, 
leukocytes, and resident cells at the site of tissue injury bring about the fundamental 
physiological changes that define acute inflammation: vasodilation, increased vascular 
permeability, and leukocytic emigration (Kumar et al., 2018). Although inflammation is 
protective, it can have deleterious effects on the host (Derry et al., 2009). Acute postoperative 
pain results from tissue injury (from a mucosal incision, bone removal, tissue retraction, tooth 
division and removal, closure of the surgical site) and surgery-mediated inflammation.  
 
NSAIDs are renowned for their anti-inflammatory properties and analgesic efficacy against 
mild-to-moderate postoperative pain (Derry et al., 2009). Arachidonic acid metabolites are 
critical components of acute inflammation and are central to the understanding of the 
mechanism of action of NSAIDs (Figure 4).  
 
Tissue injury releases arachidonic acid from cellular membrane phospholipids, which then 
becomes oxidised into two major classes of bioactive metabolites: prostaglandins through the 
enzyme, cyclooxygenase; and leukotrienes by 5-lipoxygenase (Kumar et al., 2018). These 
metabolites, also known as eicosanoids, are capable of mediating and modulating inflammatory 
processes. For this reason, the enzymes that generate eicosanoids are the inhibitory targets of 
many anti-inflammatory drugs. Prostaglandins, synthesised via cyclooxygenase pathway, are 
particularly important because, not only are they responsible for maintaining various 
homeostatic functions (for example, regulating renal haemodynamics, haemostasis, 
gastromucosal integrity), they also mediate and modulate pathophysiological processes 
involved in local and systemic inflammation. Prostaglandins induce vascular changes 
(vasodilation and increased vascular permeability), activate nociceptors, and promote platelet 
aggregation (Dallob et al., 2003). Therefore, preventing prostaglandin production in the setting 
of tissue injury will help to reduce inflammation and pain (Hawkey, 1999). Leukotrienes are 




seen in asthma and allergic reactions (Kumar et al., 2018). Since leukotrienes and lipoxins are 
not directly associated with pain, they will not be discussed further in this thesis. 
 
Figure 4. Production of eicosanoids from arachidonic acid and their roles in inflammation 




By controlling the pathological severity of inflammation, NSAIDs lessen the intensity of the 
external signs of acute inflammation: pain, facial swelling, and loss of function (manifesting as 
restricted mouth opening) (Kumar et al., 2018). NSAIDs suppress the synthesis of 
prostaglandins by inhibiting cyclooxygenases: cyclooxygenase-1 (COX-1) and 
cyclooxygenase-2 (COX-2). COX-1 is a ubiquitous enzyme expressed in most tissues; given 
its role in mediating normal physiological processes, it is considered a house-keeping isoform. 
By contrast, COX-2 is inducible, meaning that its expression depends on the presence of 
inflammation (Hawkey, 2001). NSAIDs can be subdivided into nonselective and selective 




analgesic effects (Clarke et al., 2014). However, their safety profiles differ, making the selection 
of one group preferable to the other in certain clinical situations. An overview of adverse events 
associated with COX-1 and COX-2 inhibitors is provided in Section 2.2.2. 
 
 Adverse events associated with COX-1 and COX-2 inhibitors 
 
A recent systematic review involving a total of 35,000 young and healthy study participants 
showed that the adverse event profile of a single oral dose of NSAIDs was similar to placebo, 
except for high doses of aspirin (Moore et al., 2015a). This confirms the safety of short-term 
NSAID use. However, long-term use is limited by their adverse events (Fitzgerald & Patrono, 
2001). This could be a problem when managing postoperative complications such as alveolar 
osteitis and infection, which often require prolonged analgesia. Thus, it is important to be 
cognisant of the notable adverse effects associated with NSAIDs: gastrointestinal; 
cardiovascular; renal; and haematological effects. 
 
Gastrointestinal adverse effects 
 
Conventional nonselective NSAIDs, like ibuprofen and aspirin, have a dual suppressive 
function against COX-1 and COX-2 enzymes. Gastrointestinal adverse effects (such as mild 
dyspepsia, gastric irritation, ulceration, and bleeding) are commonly associated with 
conventional NSAID use (Fitzgerald & Patrono, 2001). Reportedly, up to 60% of patients on a 
regular NSAID regimen have gastric erosions and about 10%-30% have gastric ulcers (Laine, 
1996). Gastrointestinal toxicity is attributed to the inhibition of protective prostaglandin 
synthesis via COX-1 blockade. Prostaglandins ensure gastrointestinal protection by secreting 
mucus and maintaining a protective waxy surface layer over the luminal surface. Thus, 
suppression of prostaglandin release impairs the innate defence against luminal insults and 
predisposes susceptible individuals to gastrointestinal complications (Hawkey, 2001). Coxibs 
such as celecoxib and etoricoxib selectively inhibit inducible COX-2 isoforms, leaving the 
protective COX-1 unaffected (Clarke et al., 2014). The selective strategy intends to provide an 
alternative that is as efficacious as conventional NSAIDs from the anti-inflammatory and 
analgesic standpoints but with better gastrointestinal tolerability (Hawkey, 2001). Indeed, the 
better gastrointestinal safety of COX-2 inhibitors has been highlighted in the rheumatology 
literature (Bombardier et al., 2000; Laine et al., 2007; Moore et al., 2005; Nissen et al., 2016; 





Cardiovascular adverse effects 
 
Since the introduction of COX-2 inhibitors, concerns have been raised about an elevated 
cardiovascular risk (Clarke et al., 2014). It is hypothesised that a thromboxane-prostacyclin 
imbalance is a central mechanism by which the coxibs seem to increase cardiovascular risk 
(Grosser et al., 2006). COX-1-derived thromboxane (TXA2) is a potent platelet-aggregating 
inducer and its action is counter-regulated by COX-2-derived prostacyclin (PGI2). Selective 
suppression of PGI2 by COX-2 inhibitors while preserving COX-1-mediated TXA2 release 
would shift the balance towards a prothrombotic state, thereby potentially increasing the risk of 
myocardial infarction and stroke. The Adenomatous Polyp Prevention on Vioxx (APPROVe) 
trial was terminated early because of the greater cardiovascular hazard associated with chronic 
rofecoxib use (Bresalier et al., 2005), leading to its global withdrawal in 2004 (US Food & Drug 
Administration, 2004). A similar study of celecoxib revealed a dose-related increase in 
cardiovascular risk (Solomon et al., 2005). However, the recent Prospective Randomised 
Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen study (PRECISION) 
reassured clinicians and researchers that moderate doses of celecoxib (100mg-200mg twice a 
day) had a comparable cardiovascular risk to those of ibuprofen (600mg-800mg three times a 
day) and naproxen (375mg-500mg twice a day) in patients with rheumatoid arthritis or 
osteoarthritis (Nissen et al., 2016). A similar finding was observed with etoricoxib (60mg or 
90mg daily) and diclofenac (150mg daily) in the Multinational Etoricoxib and Diclofenac 
Arthritis Long-term (MEDAL) program (Cannon et al., 2006). 
 
Renal adverse effects 
 
NSAIDs, including COX-2 inhibitors, can have detrimental renal adverse effects (Clarke et al., 
2014), particularly in patients with pre-existing renal insufficiency. Inhibiting renal 
prostaglandin biosynthesis impairs critical physiological processes, especially the maintenance 
of fluid and electrolyte homeostasis and renal haemodynamics. Compromised renal perfusion 
and sodium and potassium retention can precipitate fluid retention, oedema, hypertension, heart 
failure, fatal cardiac dysrhythmias, and acute renal failure (Brater, 1999; Hernández-Díaz & 
García-Rodríguez, 2001). 
 
As cardiotoxicity unique to COX-2 inhibitors became more apparent, questions also emerged 
about the nephrotoxic potential of selective COX-2 blockade. Zhang et al. (2006) evaluated 114 




inhibitors, including rofecoxib, celecoxib, and etoricoxib. Their meta-analysis demonstrated 
higher renal toxicity and arrhythmia events exclusive to rofecoxib while no significant adverse 
events were seen with the other coxibs. This finding was reaffirmed by (1) the PRECISION 
trial, which identified significantly lower rates of serious renal adverse events associated with 
celecoxib than with ibuprofen (Nissen et al., 2016), and (2) the MEDAL programme, which 
observed equivalence in the discontinuation rates of etoricoxib and diclofenac due to renal 
dysfunction (Cannon et al., 2006). Overall, the accumulating evidence indicates that the renal 
safety of coxibs approximates that of nonselective NSAIDs. 
 
Haematologic adverse effects 
 
The ability of conventional NSAIDs to suppress platelet aggregating TXA2 can theoretically 
prolong bleeding. Given the multifactorial nature of bleeding, the antiplatelet effects of NSAIDs 
alone, in an otherwise healthy individual, do not significantly interfere with haemostasis (Derry 
et al., 2009; Forrest et al., 2002). Platelet aggregation and bleeding time have not shown to be 
adversely affected by COX-2 inhibitors (Dallob et al., 2003; Straube et al., 2005). However, 
some authorities advise individuals with underlying coagulopathy, especially platelet defects, 
to avoid NSAIDs because the consequence of platelet dysfunction may be exaggerated 
(Solomon, 2020). 
 
Concomitant use of conventional NSAIDs with aspirin is contraindicated due to the former’s 
interference with the antiplatelet effects of aspirin, which undermines the cardioprotective 
effect conferred by aspirin. However, the same effect has not been observed with COX-2 
inhibitors (Catella-Lawson et al., 2001; Dallob et al., 2003; Renda et al., 2006). The combined 
use of anticoagulants and NSAIDs has a three-fold risk of developing severe haemorrhagic 
complications (Davidson et al., 2014). Cochrane et al. (2002) reported that the international 
normalised ratio (INR) was increased by 13% when etoricoxib was co-administered with 
warfarin. Moreover, a recent post hoc study in the Randomised Evaluation of Long Term 
Anticoagulant Therapy (RE-LY) trials demonstrated a significantly higher risk of bleeding 
associated with NSAIDs combined with dabigatran or warfarin (Kent et al., 2018). The resultant 
haemostatic impairment may be further compounded by the antiplatelet effects of NSAIDs 
(Patrono, 2019). Therefore, careful monitoring and dose adjustment of anticoagulants or 





 Pharmacology of NSAIDs 
 
This section will review the pharmacology of the NSAIDs relevant to this thesis: sustained-
release (SR) ibuprofen and etoricoxib. 
 
2.2.3.1 SR ibuprofen 
 
Together with rapid absorption and short elimination half-life, conventional ibuprofen demands 
a multiple-dosage regimen, typically 400mg three times a day for healthy adults, up to 3.2g in 
three divided doses under medical supervision (Derry et al., 2009). SR ibuprofen is formulated 
to allow once-daily dosing without compromising its analgesic efficacy, safety, and tolerability. 
An 800mg tablet of SR ibuprofen has a gel matrix, within which the active agent is contained. 
Once the matrix contacts the gastrointestinal aqueous medium, ibuprofen gradually diffuses 
through the eroding matrix. The SR strategy helps to sustain its therapeutic plasma 
concentrations uniformly over 24 hours, without the need for multiple dosing like that of the 
immediate-release (IR) preparation, which is characterised by its fluctuating concentration 
peaks and troughs (Baumgartner et al., 1996; Flavell Matts et al., 1993). A dosage of 1.6g of 
SR ibuprofen a day is approved, for which the area under the plasma concentration-time curve 
is similar to that of 4-times daily dosing of conventional ibuprofen 400mg (Mylan New Zealand, 
2020). It takes about 3 hours to reach its maximum plasma concentration, but this is largely 
dependent on the type of coating used for the agent (Higton, 2015; Mylan New Zealand, 2020). 
The peak plasma concentration of SR ibuprofen is similar to that of conventional ibuprofen 
(Kendall et al., 1990). 
 
IR- and SR ibuprofen have similar bioavailability (Rainsford, 2009). Ibuprofen has a small 
volume of distribution, as reflected by about 99% being bound to plasma proteins. However, it 
can accumulate in inflamed tissues to exert its anti-inflammatory and analgesic effects. The 
majority of ibuprofen undergoes hepatic metabolism, and the metabolites are rapidly eliminated 
by the kidneys, with only a minor fraction being recovered as the parent compound in urine. Its 
plasma half-life is approximately 2-3 hours and excretion is complete around 24 hours post-
administration. These pharmacokinetic parameters may be prolonged in people with pre-
existing renal impairment, but there is little evidence for any clinically significant alterations in 
people with mild to moderate hepatic impairment. Caution must be exercised when prescribing 




potential for nephrotoxicity is far greater in this age group due to their diminished elimination, 
prolonged half-life, and subsequent accumulation of ibuprofen metabolites (Rainsford, 2009). 
 
SR ibuprofen is known to be as effective and well-tolerated as its IR counterparts in managing 
chronic pain (Flavell Matts et al., 1993; O'Connor et al., 1993). The convenience of once-daily 
dosing of SR ibuprofen is its prime advantage: it obviates the risk of subtherapeutic plasma 
levels resulting from poor compliance associated with conventional ibuprofen that may, in turn, 
compromise the intended analgesic and/or anti-inflammatory therapy (Baumgartner et al., 
1996). An agent that enables prolonged delivery of therapeutic effects with minimal variations 
in peak serum concentration is certainly desirable for the management of chronic and 
postoperative pain (Baumgartner et al., 1996). Not only is SR ibuprofen recommended for 
musculoskeletal conditions, it is also indicated for relieving acute pain states in which there is 
an inflammatory component (Mylan New Zealand, 2020). In the perioperative setting, using 
SR ibuprofen may be favoured as part of a multimodal approach. It may provide more consistent 
analgesia over a longer duration with less breakthrough pain (Christensen et al., 2017); 
ibuprofen’s opioid-sparing effects (Best et al., 2017) may also reduce the need for rescue 
analgesia. With respect to conventional ibuprofen, there is a substantial body of evidence for 
its effectiveness against mild-to-moderate postoperative pain (Derry et al., 2009). However, the 
extent to which SR formulations impart their analgesic efficacy relative to their IR analogues 
in the surgical setting is unclear. It is possible that investigating SR ibuprofen in the 
perioperative setting may be confronted with significant resistance, since pain is usually acute, 
and accordingly, shortening the onset of action is considered critical (Higton, 2015). 
Nevertheless, the little information that is available on the efficacy of SR ibuprofen shows some 
promising findings: some have demonstrated its effectiveness in pain control following 
laparoscopic surgery (Owen et al., 1997) and its benefit as an adjunct to morphine patient-
controlled analgesia after gynaecological surgery (Plummer et al., 1996). Others found SR 
ibuprofen to be just as efficacious as conventional ibuprofen following third molar surgery 
(Cooper et al., 1993). The contemporary data on the effects of combined immediate-
release/extended-release formulations exhibited superior pain relief than placebo and naproxen 










Etoricoxib is a second-generation COX-2 inhibitor, approved for use in the relief of acute pain: 
pain after minor dental procedures, various forms of arthritis, and chronic musculoskeletal pain 
(Clarke et al., 2014; Merck Sharp & Dohme (NZ), 2017). It is highly selective for COX-2 
blockade; its COX-2 selectivity ratio over COX-1 is 106, which is considerably higher than the 
7.6 and 0.2 for celecoxib and ibuprofen, respectively (Riendeau et al., 2001) (Table 1). The 
recommended once-daily dosage of etoricoxib ranges from 30mg to 120mg, depending on its 
therapeutic indication. The licensed dose for acute pain is 120mg (Clarke et al., 2014). 
 
Table 1. COX-2 selectivity ratios of selective and nonselective NSAIDs 
 








Adapted from Riendeau et al., 2001 
 
Oral etoricoxib 120mg is almost completely absorbed, with a mean bioavailability of near 100%. 
About 92% of etoricoxib is bound to plasma proteins and, unlike ibuprofen, it has a substantial 
volume of distribution, which accounts for its long elimination half-life of approximately 22 
hours. Owing to its rapid absorption, etoricoxib reaches its peak plasma concentration about 
one hour following oral administration (Agrawal, Porras, et al., 2003; Cochrane et al., 2002). 
Etoricoxib undergoes extensive hepatic metabolism and its metabolite is eliminated in urine 
and faeces (Rodrigues et al., 2003). Since most etoricoxib is eliminated through metabolism, 
the rate of systemic clearance is inversely related to the degree of hepatic insufficiency. Thus, 
dose adjustment is required for patients with hepatic impairment (Agrawal, Rose, et al., 2003). 
 
In a gastric biopsy study by Dallob et al. (2003), etoricoxib had an imperceptible effect on the 
mean gastric prostaglandin synthesis rate, whereas naproxen inhibited approximately 78% of 
prostaglandin synthesis. This finding was clinically supported by the MEDAL program, which 
found a significantly lower risk of adverse gastrointestinal outcomes associated with etoricoxib 
than with diclofenac (Laine et al., 2007). Additionally, selective COX-2 blockade should not 




baseline thromboxane levels were comparably inhibited when low-dose aspirin was combined 
with etoricoxib 120mg (96.7% of platelets inhibited) or placebo (97% of platelets inhibited) 
(Dallob et al., 2003). Ouellet et al. (2001) indicated that a significantly high concentration of 
etoricoxib is required to interfere with aspirin’s antiplatelet effects. In their study, 19μmol/L of 
etoricoxib was required to counteract, by 50%, the platelets inactivated from 10μmol/L of 
aspirin, whereas 0.048μmol/L of ibuprofen was required to produce the same result (Ouellet et 
al., 2001). 
 
A dose-ranging study by Malmstrom, Sapre, et al. (2004) found that etoricoxib 120mg and 
180mg were significantly superior to ibuprofen 400mg and placebo in pain management. The 
investigators identified etoricoxib 120mg to be the minimum dose required for maximal 
analgesic efficacy against acute pain after impacted third molar surgery. When the efficacy of 
etoricoxib 120mg was compared to naproxen sodium 550mg and paracetamol/codeine 
600mg/60mg (Malmstrom, Kotey, et al., 2004), etoricoxib was just as efficacious as naproxen 
sodium and both of these were substantially better than paracetamol/codeine. Similarly, 
etoricoxib performed better than paracetamol/oxycodone 650mg/10mg (Chang et al., 2004; 
Malmstrom et al., 2005). The duration of action of etoricoxib was found to be prolonged, 
exceeding 20 hours (Chang et al., 2004; Malmstrom, Kotey, et al., 2004; Malmstrom et al., 
2005; Malmstrom, Sapre, et al., 2004). Daniels et al. (2011) who evaluated etoricoxib 90mg 
and 120mg against ibuprofen 600mg and paracetamol/codeine 600mg/60mg, revealed that: (1) 
etoricoxib 90mg and 120mg yielded similar analgesic efficacy; (2) etoricoxib had a comparable 
effect to ibuprofen 600mg; and (3) etoricoxib, regardless of its dose, was superior to 
paracetamol/codeine. Rasmussen et al. (2005) reported that etoricoxib 120mg delivered 
effective analgesia that was equivalent to a once-daily controlled-release naproxen sodium 
1100mg and reduced opioid consumption in patients who had knee or hip replacement surgery. 
No difference was observed between etoricoxib and placebo in adverse events or withdrawals 
in any of the aforementioned studies. Overall, the Cochrane systematic review concluded that 
the analgesic efficacy of single-dose etoricoxib 120mg is comparable with, if not better, than 





 Pre-emptive analgesia 
 
This section will outline the definition of pre-emptive analgesia and the current understanding 
of the concept. The review of the literature will be presented on the pre-emptive effect of SR 




Pre-emptive analgesia is the administration of an antinociceptive agent before surgical insult, 
with the intent to suppress nociceptive pathways to reduce peripheral sensitisation and prevent 
the establishment of central sensitisation (Dahl & Møiniche, 2004; Kissin, 2000). There is much 
controversy about the definition of pre-emptive analgesia, and so it will be discussed in greater 
detail in Section 2.3.3. 
 
 A brief history of the concept 
 
Crile (1913) proposed the theory, anoci-association, based on his speculation that surgical 
shock and physical exhaustion were provoked by a strong traumatic (noxious somatic stimulus) 
or psychic stimulus (intense fear and anxiety). He also made a specific assertion that these 
stimuli can induce certain changes in the CNS that bring about the phenomena of postoperative 
hyperalgesia and painful scar; these are the clinical consequences for which Crile (1913) stated 
that “mere trifles become adequate stimuli” to incite pain. Crile argued that shock and 
exhaustion can be prevented and the patient’s postoperative morbidity improved by excluding 
from the brain all the noxious stimuli or harmful associations. He termed this concept anoci-
association. To achieve this complete blockade during surgery (‘shockless operation’), using 
multimodal anaesthesia was proposed, involving: (1) general anaesthesia (GA) to prevent 
negative affectivity relating to surgery; and (2) pre-incision local anaesthesia (LA) to prevent 
intraoperative noxious input from entering the brain (Crile, 1913; Katz, 1993). 
 
In 1974, Wall et al. (1974) discovered that a brief, high-frequency afferent barrage transmitted 
by injured peripheral sensory fibres can develop a prolonged activity, which they named injury 
discharge. They later found that injury discharge can subsequently trigger prolonged spinal cord 
hyperexcitability (Wall & Woolf, 1984). Together with Woolf’s landmark paper reporting the 




rationale for exploring various techniques aimed at preventing afferent bombardment of the 
CNS during surgery. In 1988, Wall named this concept ‘pre-emptive preoperative analgesia’ 
(Wall, 1988). Since then, many experimental studies have demonstrated the positive effects of 
pre-injury administration of LA (Coderre et al., 1990; González-Darder et al., 1986), opioids 
(Dickenson & Sullivan, 1987; Woolf & Wall, 1986), and N-methyl-D-aspartate (NMDA) 
receptor antagonists (Seltzer et al., 1991) for preventing the state of central hyperexcitability 
following injury and transition of acute to chronic pain. These encouraging findings promoted 
undertaking trials focusing on preventing acute and chronic postoperative pain by initiating 
analgesia before making the initial surgical incision (Katz et al., 2011). 
 
2.3.2.1 Pre-emptive analgesia 
 
Three distinct pre-, intra-, and postoperative phases make up the perioperative period. Pre-
emptive analgesia underscores the significance of the timing of intervention relative to surgical 
incision. The initiation of an antinociceptive agent before surgery assumes that incision and 
surgical manipulation are responsible for the generation of high-intensity noxious stimulation 
that, in turn, contributes to the sustained and intense nociceptive bombardment of the CNS. 
Therefore, the analgesic effect must cover the pre- and intraoperative phases to serve its 
fundamental purpose: to protect the central nociceptive circuits from the afferent nociceptive 
barrage arising from the surgery. Clinically, this objective translates into reducing acute pain 
and pre-empting the establishment of chronic postsurgical pain. 
 
Unfortunately, the published literature lacks uniformity in the definition of pre-emptive 
analgesia, leading to much confusion and controversy (Katz et al., 2011; Kissin, 2000). Kissin 
(2000) identified three different definitions presented in publications: 
 
“Treatment that: (1) starts before surgery; (2) prevents the establishment of central 
sensitisation caused by incisional injury (covers only the period of surgery); and (3) prevents 
the establishment of central sensitisation caused by incisional and inflammatory injuries 
(covers the period of surgery and the initial postoperative period).” (p. 1138) 
 
Kissin (2000) stated that the first definition, which is most widely used, is misleading because 
it is concerned only with the timing of treatment initiation and neglects the adequacy of 
antinociception. The classic study design consists of two study groups with identical 




incisional (Dahl & Møiniche, 2004; Katz et al., 2011). There are two inherent flaws here. First, 
without the presence of an appropriate control group (that is, placebo), any observed effect may 
be due to a better analgesic effect of the short-acting agent given post-incision while the clinical 
effect of the same agent given pre-incision has subsided. Second, according to this definition, 
an inadequate nerve block given before surgery would still be considered pre-emptive analgesia. 
This is false because suboptimal nerve block, although given preoperatively, does not confer 
any analgesic effect in the first instance. Interpretation of the ‘negative result’ as per the first 
definition, then, unintentionally leads to a false conclusion that pre-emptive analgesia is 
ineffective when a true effect may exist if the studied agent had a longer duration of action or 
if the nerve block was profound before surgery (Dahl & Kehlet, 2011; Katz et al., 2011; Kissin, 
1996; Kissin, 2000). Another point to consider is that inadequate intervention poses a 
significant threat to the outcome of meta-analysis. Kissin (2011) stressed that controlling for 
treatment integrity (for example, adequacy of nerve block, degree, and duration) is often 
ignored and, if studies with inadequate treatment are included in a meta-analysis, this can result 
in an erroneous conclusion. 
 
The second definition also is time-restrictive. It denotes that central sensitisation arises only 
from the intraoperative noxious stimuli. Negative findings from the studies adopting this 
definition must be interpreted with care because they ignore any contributions from the 
postoperative, inflammation-mediated secondary phase of injury. Simply put, a tissue wound 
because of surgery is painful and thus, can induce central sensitisation if postoperative pain and 
inflammation (that is, peripheral sensitisation) are inadequately managed. Based on this 
definition, the analgesic effect is operational only during the time of surgery; any observed 
effect from this study design can potentially be different if the antinociceptive effect continues 
through to the postoperative period. This narrow view forms the justification of those who 
consider pre-emptive analgesia clinically irrelevant (Kissin, 2000). This leads to the third and 
proper definition, which is broader to emphasise the need for an intervention to suppress both 
surgical and inflammatory injuries to pre-empt the development of central hyperexcitability 
(Kissin, 2000). Surprisingly, clinical trials embracing this definition are scarce. 
 
While many animal studies have shown promising findings on the value of pre-emptive 
analgesia, this has not been replicated to the same extent in human clinical trials (Dahl & Kehlet, 
2011; Kissin, 1996). Some have reported significant findings in favour of pre-emptive analgesia 
(Gottschalk et al., 1998; Katz et al., 2003; Şen et al., 2009), while others have reported either 




antinociceptive agents (Ong et al., 2005). Inconsistent use of definitions of pre-emptive 
analgesia has contributed to the lack of standardisation in treatment protocols and methods of 
outcome evaluation, thereby making the interpretation of the results confusing and 
controversial (Clarke et al., 2015; Dahl & Kehlet, 2011; Katz et al., 2011; Kissin, 2000). 
 
 Pre-emptive efficacy of ibuprofen and etoricoxib in third molar surgery 
 
A recent meta-analysis showed positive effects of pre-emptive NSAID use in improving 
postoperative pain and reducing the demand for rescue analgesia after third molar surgery 
(Cetira Filho et al., 2020). Surgeons’ preference for pre-emptive administration of etoricoxib 
over conventional NSAIDs (such as ibuprofen) may be on the basis that etoricoxib: (1) has a 
longer duration of action; and (2) may have better analgesic and anti-inflammatory effects than 
traditional NSAIDs, with the added value of a better gastrointestinal safety profile (Clarke et 
al., 2014). There is a lack of research comparing the pre-emptive analgesic effect of etoricoxib 
with long-acting SR ibuprofen. Accordingly, a narrative review and critical appraisal of the 
relevant literature was completed. 
 
The literature search was conducted in four electronic databases: PubMed; Medline; EMBASE; 
and Cochrane Central Register of Controlled Trials. The search keywords included: pre-
emptive, protective, or preoperative terms; etoricoxib or ibuprofen, including generic and 
tradenames, coxibs, sustained-release, or modified-release; and third molar terms. The Boolean 
operators were used and the results were limited to English-language articles. 
 
The search yielded six randomised control trials investigating pre-emptive analgesic effects of 
(1) etoricoxib (Costa et al., 2015); (2) etoricoxib versus ibuprofen (Albuquerque et al., 2017); 
(3) etoricoxib versus dexamethasone (Rodrigues et al., 2019; Sotto-Maior et al., 2011); (4) 
rofecoxib versus ibuprofen (Morse et al., 2006); and (5) ibuprofen versus SR ibuprofen (Yong 
& Coulthard, 2010). The key features of the studies are presented in Tables 2 to 6, followed by 
an overview of the findings, including the strengths and weaknesses of each study. Finally, the 
significance of the present study is evaluated in the context of filling the gaps in current 














Number of third molars Study 
duration 
       
Costa et al. 
(2015) 




18 to 35 Bilateral impacted 












Active control: 24 
Placebo: 24 
18 to 35 Bilateral impacted 








Dexamethasone 4mg Intervention: 25 
Active control: 25 
18 to 27 Bilateral impacted 







Etoricoxib 90mg Intervention: 19 
Active control: 19 
18 to 32 Bilateral impacted 
mandibular third molars 
7 days 
 
Morse et al. 
(2006) 





Active control: 16 
Placebo: 16 

















Bupivacaine 0.5% with 
adrenaline 1:200k 
Intervention: 50 
Active control: 48 
18 and 
above 
Third molars, not specified 2 days 





Table 3. Design characteristics of the six relevant studies 
       
Reference 
(year) 




Information about the 
preoperative status 
Pell & Gregory 
impaction type 
Bone removal +/- 
tooth sectioning 
       
Costa et al. 
(2015) 





• ASA I 
• No periodontal disease, 
swelling, fever, trismus, or 
acute inflammatory or 
infectious disease  
• No use of NSAIDs within 3 
weeks preoperatively 
Class I, II 




       
Albuquerque 
et al. (2017) 
Ibuprofen 300mg • Pain 
• Swelling 
• Trismus 
• Tissue levels of 
TNF-α and   
IL-1β 
• ASA I 
• No periodontal disease, 
swelling, fever, trismus, or 
acute inflammatory or 
infectious disease  
• No use of NSAIDs within 3 
weeks preoperatively 
Class I, II, III 
Positions A, B, 
C 
Yes 
       
Sotto-Maior 
et al. (2011) 





• Asymptomatic mandibular 
third molars 
• No periodontal disease, 
acute pericoronitis, or pre-
existing local or systemic 
problem 
• No recent anti-
inflammatory treatment 
Class I, II 
Positions A, B 
Yes 













Information about the 
preoperative status 
Pell & Gregory 
impaction type 
Bone removal +/- 
tooth sectioning 
       
Rodrigues et 
al. (2019) 





• Absence of systemic 
disease 




• Absence of signs of 
infection from third molar 
sites 
Not specified Yes 
       
Morse et al. 
(2006) 
Paracetamol 1g Pain Rescue analgesic 
consumption 
 
• ASA I 
• No psychological or 
psychiatric conditions 
• No use of psychotropic 
medications 
• No use of analgesics within 
12 hours preoperatively 
Not specified Not specified 






Pain • Rescue 
analgesic 
consumption 
• ASA I or II 
• No use of analgesics within 
48 hours preoperatively 
Not specified Yes 
















     
Costa et al. 
(2015) 
0, 2, 4, 6, 8, 
10, 12, 24h 
Day 2, 3, 5, 7 
10cm VAS The etoricoxib group had less pain than the placebo group at all postoperative time 
points until Day 2 
 
More participants in the placebo group consumed rescue analgesic than the 
etoricoxib group (data presented in a graph only) 
 
By 8 hours, all participants in the placebo group had consumed rescue analgesic; 
29% of participants in the etoricoxib group did not consume rescue analgesic 
 
The placebo group took a shorter time to consume rescue analgesic (4 hours) than 
the etoricoxib group (27.6 hours) 
 
The overall rescue analgesic consumption was greater in the placebo group (4 
capsules) than the etoricoxib group (1.6 capsules) 
Not specified 
     
Albuquerque 
et al. (2017) 
0, 2, 4, 6, 8, 
10, 12, 24h 
Day 2, 3, 5, 7 
10cm VAS The etoricoxib group had less pain than the placebo group at all postoperative time 
points until 10 hours 
 
The ibuprofen group had less pain than the placebo group during the immediate 
postoperative period 
 
The etoricoxib group had lower mean accumulated pain than the ibuprofen group 
during the first 12 hours 
Not specified 
     















     
Sotto-Maior 
et al. (2011) 
0h 
Day 1, 2 
10cm VAS There was no difference between the etoricoxib and dexamethasone groups in the 
postoperative pain level 
 
There was no difference between the etoricoxib and dexamethasone groups in the 
number of rescue analgesics consumed  
Not specified 








10cm VAS There was no difference between the dexamethasone and etoricoxib groups in the 
postoperative pain level  
 
There was no difference between the dexamethasone and etoricoxib groups in the 
amount of rescue analgesic consumed 
Not specified 
     




mins until 6h 
after surgery 
10cm VAS The rofecoxib and ibuprofen groups had less pain than the placebo group 
 
There was no difference in the postoperative pain level between the rofecoxib and 
ibuprofen groups 
 
The placebo group required more rescue analgesia than the rofecoxib and ibuprofen 
groups 
 
There was no difference between the rofecoxib and ibuprofen groups in the rescue 
analgesic consumed  
 




























There was no difference in the postoperative pain level between the SR- and 
conventional ibuprofen groups 
 
More participants in the SR ibuprofen group (96%) were satisfied with their overall 
pain control than the conventional ibuprofen group (87.5%) 
 
Participants in the SR ibuprofen group took longer time to consume rescue analgesic 
(3.2h) than the conventional ibuprofen group (2.7h) 
 
More participants in the SR ibuprofen group consumed rescue analgesic (92%) than 
the conventional ibuprofen group (87.5%) 












Table 5. Findings of the six relevant studies specific to swelling 
Reference (year) Time of 
measurement 
Method of measurement Findings 
    
Costa et al.   
(2015) 
0, 24, 72h 
Day 5, 7 
Separate measurements from the mandibular angle to: 
1. Tragus 
2. Lateral canthus of the eye 
3. Ala of the nose 
4. Labial commissure 
5. Soft pogonion 
There was no difference between the two groups at 
any given time point 
Albuquerque et al. 
(2017) 
0, 24, 72h 
Day 7 
Separate measurements from the mandibular angle to: 
1. Tragus 
2. Lateral canthus of the eye 
3. Ala of the nose 
4. Labial commissure 
5. Soft pogonion 
There was no difference between the three groups at 
any given time point 
Sotto-Maior et al. 
(2011) 
0, 24, 48h Sum of 3 measurements: 
1. Tragus to the labial commissure 
2. Mandibular angle to ala of the nose 
3. Mandibular angle to the soft tissue pogonion 
There was no difference between the two groups at 
any given time point 







Separate measurements from the mandibular angle to: 
1. Tragus 
2. Lateral canthus of the eye 
3. Ala of the nose 
4. Labial commissure 
5. Soft pogonion 
Participants in the etoricoxib group had slightly more 
swelling than the dexamethasone group, but the 
difference was so small as to not be clinically 
significant 
Morse et al. (2006) - - - 
Yong & Coulthard 
(2010) 





Table 6. Findings of the six relevant studies specific to trismus 
 
 
Reference (year) Time of 
measurement 
Method of measurement Findings 
    
Costa et al. (2015) 0h, 24h, 72h 
Day 5, 7 
Maximum interincisal distance There was no difference between the two groups at any given time 
point 
    
Albuquerque et al. 
(2017) 
0h, 24h, 72h 
Day 7 
Maximum interincisal distance The etoricoxib group had less trismus than the placebo and 
ibuprofen groups at all time points 
    
Sotto-Maior et al. 
(2011) 
0, 24, 48h Maximum interincisal distance There was no difference between the two groups at any given time 
point 
    







Maximum mouth opening 
(reference points not specified) 
There was no difference between the two groups at any given time 
point 
    
Morse et al. (2006) - - - 
    
Yong & Coulthard 
(2010) 
- - - 






Costa et al. (2015) examined the pre-emptive analgesic and anti-inflammatory effectiveness of 
etoricoxib in third molar surgery. This split-mouth, triple-blind, placebo-controlled randomised 
control study found a significant reduction in pain and the demand for rescue analgesia during 
the first 48-hour postoperative period when etoricoxib 120mg was orally administered 1 hour 
before surgery. Pre-emptive etoricoxib, when compared to placebo, delayed the mean time 
taken to consume the first rescue analgesic agent (27.6 hours versus 4 hours). Postoperative 
facial swelling and mouth opening were comparable between the etoricoxib and placebo groups. 
The investigators are commended for conducting a pilot study to estimate a sample size 
appropriate to its split-mouth design and detailed reporting on blinding and randomisation. 
Attempts were made to reduce confounders by selecting study participants with bilateral 
mandibular third molars of similar degree of impaction, while those with pericoronitis, local or 
systemic signs of infection, or history of NSAID use within 3 weeks preceding the surgery had 
been excluded. However, the split-mouth design may be its weakness and this will be discussed 
later in detail. It is noteworthy, there was no disclosure of whether patients with known 
psychological or psychiatric conditions and/or on any psychotropic drugs were included or 
excluded. Psychological vulnerability negatively affects pain perception and may be an 
important factor that converts acute pain to persistent postsurgical pain (Dahl & Kehlet, 2011). 
Psychotropic drugs, owing to their centrally acting mechanism and analgesic properties, are 
capable of interfering with pain perception and interpretation. Inclusion of such patients in a 
trial can inadvertently contaminate the postoperative pain data and lead to false conclusions. 
 
Albuquerque et al. (2017) used a similar study design to compare the pre-emptive efficacy of 
etoricoxib 120mg with that of ibuprofen 400mg and placebo. Participants who received 
etoricoxib or ibuprofen 1 hour before surgery had significantly less pain in the acute 
postoperative period than those who received a placebo. The mean accumulated pain during 
the first 12 hours was significantly lower in the etoricoxib group than in the ibuprofen group. 
Beyond the 12-hour mark, there was no statistically significant difference in pain levels 
between the two groups, despite the authors observing a consistently low pain level in the 
etoricoxib group throughout the study period. By day 5, participants who received etoricoxib 
and ibuprofen had virtually no pain. In the placebo group, pain, albeit much lower, persisted 
up to day 7. Consistent with the observations of Costa et al. (2015), there were no differences 
in facial swelling among the three study groups. Contrarily, participants in the etoricoxib group 




this was a well-structured study but not without limitations. As a secondary objective, the 
investigators examined the pre- and post-incisional differences in the proinflammatory 
cytokine levels (TNF-α and IL-1β) in gingival tissues and their association with postoperative 
pain, swelling, and trismus. Despite reductions in the cytokine levels seen in the etoricoxib and 
ibuprofen groups 30 minutes after the incision was made, cytokine levels at this time point 
were comparable to those found in placebo. The authors concluded that, the greater the COX-
2 selectivity of NSAIDs, the lower the tissue levels of TNF-α and IL-1β, and the lower the 
inflammatory clinical outcomes of pain, swelling, and trismus. However, their presentation of 
those findings was ambiguous and difficult to comprehend. The reported associations between 
the cytokine levels (induced by preoperative administration of etoricoxib or ibuprofen) and the 
clinical parameters lack uniformity and contradicted the definitive inference made by the 
authors (see above). It is also important to note the sample size calculation. It was based on a 
similar interventional study comparing the pre-emptive analgesic efficacy between celecoxib, 
ibuprofen, and placebo (Al-Sukhun et al., 2012). However, the investigators appeared to plan 
their sample size according to the effect of pre-emptive analgesia on the changes in the cytokine 
level. This conflicts with the primary outcome of Al-Sukhun’s study and raises a question of 
whether the Albuquerque et al. study sample size was appropriate to answer their research 
questions. 
 
Sotto-Maior et al. (2011) compared the preoperative anti-inflammatory effects of etoricoxib 
120mg and dexamethasone 4mg. The duration of their study was 48 hours, within which there 
were no intergroup differences in the pain level; the total number of rescue analgesic consumed; 
facial swelling; and mouth opening. Considering that a single preoperative bolus of 
corticosteroid, especially dexamethasone, is proven to control pain and facial swelling 
following third molar surgery (Almeida et al., 2019), understanding how its pre-emptive 
efficacy compares to the less-known effects of etoricoxib is highly relevant. Although a well-
intentioned study, the critical methodological flaws of this clinical trial make it susceptible to 
bias. First, there were no details of the randomisation process. It is important to ascertain the 
adequacy of randomisation; ‘open’ randomisation methods, such as sequence generated by date 
of birth or medical record number, are considered inferior to a computer-generated 
randomisation because the former offers less protection against selection bias (Young & 
Solomon, 2003). Second, there was no detail provided regarding blinding, which adds to further 




sample size determination and the proportion of dropouts or withdrawals. A total of 50 
participants were recruited but the exact number analysed was not explicitly stated. It is 
uncertain whether there were dropouts in the trial and if so, whether appropriate statistical 
analyses were used to account for this. In light of these findings, the conclusions of this study 
need to be considered with caution. 
 
In a similar study by Rodrigues et al. (2019), participants were randomly allocated to either the 
dexamethasone 4mg group (intramuscular route to medial pterygoid muscle immediately after 
LA) or etoricoxib 90mg group (orally administered 1 hour preoperatively). The findings of this 
study closely resemble those reported by Sotto-Maior et al. (2011): the postoperative pain level, 
the total number of rescue analgesics consumed, and mouth opening were comparable between 
the etoricoxib and dexamethasone groups at day 3 and day 7. Participants who received 
etoricoxib experienced more oedema than those who had dexamethasone, but the difference 
was too small to be clinically significant. Out of all the trials concerned with the pre-emptive 
effect of etoricoxib in third molar surgery, this is singled out for excluding patients diagnosed 
with psychological or psychiatric conditions, as well as those who were on psychotropic 
medications. However, the findings of this study need further scrutiny before interpretation. 
There is no indication of any dropouts. The overall study duration was 7 days and the pain level, 
swelling, and mouth opening were measured preoperatively, immediately postoperatively, and 
on day 3 and day 7. Unlike these parameters, no time specification was made in respect of the 
total number of rescue analgesics consumed in each study group. It reveals providing 12 tablets 
of paracetamol 750mg to each participant for use as required for rescue analgesia. There is no 
information as to whether participants had any regular analgesic regimen other than the rescue 
paracetamol. The mean number of paracetamol tablets taken was 1.6 in the etoricoxib group 
and 1.4 in the dexamethasone group. It is difficult to verify whether these numbers are valid 
without knowing the exact duration of data collection and whether participants needed to resort 
to other analgesics apart from the rescue analgesia provided by the investigators. Suppose the 
rescue analgesic data were collected over 7 days and none of the participants took any other 
analgesics, one would have little confidence in the evidence that participants took only, on an 
on-demand basis, an average of fewer than 2 tablets of paracetamol 750mg over 7 days 
following an impacted mandibular third molar removal that required tooth sectioning and bone 
removal. Thus, it is difficult to draw firm conclusions on the pre-emptive efficacy of etoricoxib 





Other than the clinical trial by Albuquerque et al. (2017), no study has compared the pre-
emptive analgesic efficacy of etoricoxib and ibuprofen. Hence, the study reported by Morse et 
al. (2006) comparing the pre-emptive efficacy of orally administered rofecoxib, a highly 
selective COX-2 inhibitor, with ibuprofen is worth reviewing. Although rofecoxib was 
withdrawn in the mid-2000s, the findings from studies that scrutinise its various 
pharmacological effects serve as a useful comparator for other COX-2 inhibitor studies. This 
double-blind study had the participants randomly allocated to receive rofecoxib 50mg, 
ibuprofen 400mg, or placebo 1 hour preoperatively. It found that rofecoxib and ibuprofen 
performed better than placebo in attenuating postoperative pain and that the pre-emptive 
analgesic efficacy of ibuprofen was just as good as (if not better than) rofecoxib. A similar 
finding was seen in the use of rescue analgesia; fewer participants in the ibuprofen group 
needed rescue analgesia (25%), followed by rofecoxib (50%) and placebo (94%). This study 
suggests that pre-emptive analgesia provided by ibuprofen, a non-selective COX inhibitor, may 
be as efficacious as rofecoxib, a selective COX-2 inhibitor. However, there is no detailed 
information on the index of surgical difficulty and whether bone removal and/or tooth 
sectioning was required. Multiple surgeons were involved, meaning that surgical 
inconsistencies among different operators were likely, thus making this study susceptible to 
performance bias. Unlike the above-mentioned split-mouth trials, this study was of short 
duration (6 hours) and only one impacted mandibular third molar was surgically extracted. 
Furthermore, a small sample size (16 participants in each study group) and no reference to 
randomisation and blinding procedures make this study at high risk of bias. 
 
There is no clinical trial to date that has compared the pre-emptive efficacy of etoricoxib 120mg 
and SR ibuprofen 1.6g for acute postoperative sequelae after third molar surgery. Yong and 
Coulthard (2010) remain the only investigators to elucidate the difference in such efficacy 
between SR ibuprofen and conventional ibuprofen. In their double-blind, single-centre 
randomised control trial, participants were randomly allocated to receive either SR ibuprofen 
1.6g or conventional ibuprofen 400mg 2 hours preoperatively. All underwent third molar 
surgery under GA. There was no intergroup difference in the postoperative pain level over 48 
hours: VAS at 24 hours for the SR and conventional groups were 25mm and 26mm, 
respectively; VAS at 48 hours was 35mm and 24mm, respectively. The SR group performed 




(3.2 hours versus 2.7 hours), but more participants in the SR group consumed rescue analgesic 
(92%) than the conventional group (85%). Overall, 96% of the SR group was satisfied with 
pain control compared with 87.5% in the conventional group. The Yong and Coulthard study 
was well-conducted and its credibility lies in its robust methods. The authors acknowledged 
that perioperative opioid and/or non-opioid analgesics are often co-administered as part of 
routine GA that may confound the effects of their ibuprofen interventions. In an attempt to 
address this issue and to ensure some degree of standardisation, a specific GA protocol was 
devised, including avoidance of: (1) all opioids, except for remifentanil or alfentanil to facilitate 
induction only if necessary; (2) non-opioid analgesics; (3) nitrous oxide; and (4) 
dexamethasone. As well as this, the complete GA protocol was reported. It had an adequate 
sample size (n = 119), and a reasonable dropout rate (n = 21 lost, at 18%) and the reasons for 
exclusion were clearly described. However, one may comment that pre-incisional inferior 
dental block using bupivacaine 0.5% with adrenaline 1:200,000 could have masked the true 
pre-emptive analgesic effectiveness of SR- and conventional ibuprofen. The use of long-acting 
bupivacaine was intentional, as guided by the principle of multimodal therapy, a strategy 
endorsed by anaesthetists to maximise the pre-emptive analgesic effect (Dahl & Kehlet, 2011). 
Minor flaws of this study include a lack of specific details on the third molar characteristics, 
and the involvement of five different surgeons. However, the authors endeavoured to minimise 
performance bias by selecting surgeons of similar experience and by standardising surgical 
technique. 
 
Despite the discrepancy in the definition of pre-emptive analgesia in the published literature, it 
is interesting to note that all of the studies discussed above consistently designed the trial 
according to the most widely accepted definition of pre-emptive analgesia: the administration 
of antinociceptive agent before surgery. Another intriguing factor is that all of the investigators 
excluded anyone who had: (1) current or recent history of pain relating to third molars and/or 
elsewhere in the body; (2) local and/or systemic symptoms and signs of inflammatory or 
infectious conditions; and (3) taken analgesics within a defined period before surgery. While 
most studies did not mention central sensitisation being a fundamental component of pre-
emptive analgesia, it is conceivable based on these exclusion criteria that the investigators 
intuitively sought to eliminate factors that may have otherwise induced central sensitisation 





There are several limitations shared by all the studies discussed above. The first issue is the 
split-mouth design of the clinical trials. Four out of 6 trials reviewed here were based on the 
split-mouth model. The major distinctive feature of this design is that intergroup comparisons 
are made on a within-patient basis rather than a between-patient basis (Hujoel, 1998). This is 
an attractive quality as elimination of inter-individual biological and other differences (such as 
demographic characteristics, systemic conditions, oral hygiene status, and health habits) 
minimises error and thus improves the interpretability and precision of treatment effects. 
Another advantage lies in its economic value, since smaller sample sizes are adequate to detect 
a difference between interventions. However, the potential danger of this design is a carry-
across effect. It means an effect arising from treatment to one side of the mouth can ‘carry over’ 
or influence the response of the treatment to the other side of the mouth. This is particularly 
critical in third molar trials investigating pre-emptive analgesia; the initial experience of 
postoperative pain from the first third molar removal can alter the perception of the subsequent 
pain arising from the second third molar surgery. Although the clinical trials had an interval of 
at least 3 weeks to allow for recovery between the two extractions, it cannot completely rule 
out possible changes in pain-related behaviour as a result of the former surgery that may carry 
over to affect the pain response to the latter surgery. In short, having pain before surgery can 
worsen the postoperative pain (Dahl & Kehlet, 2011). Such effects can bias the treatment 
effects that in turn, undermine the validity of the findings (Hujoel & Derouen, 1992). 
Considering this flaw, the split-mouth design is inappropriate for clinical trials evaluating the 
efficacy of pre-emptive analgesia. 
 
Second, the sample sizes were generally small. Two split-mouth trials had conducted pilot 
studies to determine appropriate sample sizes: Costa et al. (2015) (n = 22) and Rodrigues et al. 
(2019) (n = 19). The other two studies had based this on previously reported data: Albuquerque 
et al. (2017) (n = 36) and Yong and Coulthard (2010) (n = 119). However, no information is 
available about sample size determination for the studies by Morse et al. (2006) (n = 55) and 
Sotto-Maior et al. (2011) (n = 50). Small sample sizes can result in Type II error which can 
lead to failure in detecting a difference when such a difference truly exists (that is, false 
negative results) (Gupta et al., 2016). 
 
Lastly, none of the aforementioned studies has taken account of oral-health-related quality of 




In other words, the intensity of pain and report of analgesic consumption cannot be considered 
the only variables related to the complex nature of postoperative pain (Katz et al., 2011). As 
psychosocial factors are intimately linked to the severity and chronicity of pain, some 
recommend pre- and postoperative assessment for psychological, emotional, and social 
domains of health. These additional assessments may help determine patient-related factors 
that may be associated with severe acute postoperative pain and its progression to chronic pain 




The available published evidence has demonstrated the pre-emptive efficacy of etoricoxib and 
short-acting conventional ibuprofen in attenuating immediate postoperative pain in impacted 
third molar surgery. However, data on the performance of long-acting SR ibuprofen is lacking 
in publications addressing third molar surgery. Inclusion of a long-acting NSAID within a 
perioperative multimodal analgesic armamentarium seems more appropriate to provide 
consistent and stable analgesia over a longer period with less potential for breakthrough pain. 
The only study which tested this hypothesis (Yong & Coulthard, 2010) returned equivocal 
findings, with no substantial and consistent differences between the conventional and SR 
ibuprofen groups in terms of the level of postoperative pain and analgesic demands after third 
molar surgery. Oral etoricoxib 120mg and SR ibuprofen 1.6g have a prolonged duration of 
action of at least 20 hours. Yet, no high-quality, double-blind, randomised control trial has 
compared the efficacy of pre-emptive SR ibuprofen and etoricoxib in third molar surgery. 
Moreover, no study has endeavoured to understand the impact of pre-emptive analgesia on 
postoperative quality of life. This leads to the following clinical questions: (1) how does the 
pre-emptive SR ibuprofen 1.6g compare to etoricoxib 120mg in controlling postoperative pain, 
swelling, and trismus after bilateral impacted mandibular third molar surgery; and (2) how does 








 General aim 
 
The general aim of this study was to compare the effect of pre-emptive administration of SR 
ibuprofen 1.6g and etoricoxib 120mg on adverse postoperative outcomes in surgery for the 
removal of bilateral impacted mandibular third molars. 
 
 Specific objectives 
 
The specific objectives of this study were to compare the effect of pre-emptive administration 
of SR ibuprofen 1.6g and etoricoxib 120mg on pain, swelling, trismus, and the quality of life 
following surgical removal of bilateral impacted mandibular third molars. 
 
 Study hypothesis 
 
The pre-emptive effect of SR ibuprofen 1.6g and etoricoxib 120mg on postoperative pain, 
swelling, trismus, and the quality of life is comparable. 
 
 Research significance 
 
If the proposed study demonstrates that SR ibuprofen is equal or better than etoricoxib, then 
routine pre-emptive use of SR ibuprofen in third molar surgery would be more cost-effective 
than the use of the expensive etoricoxib. Conversely, if etoricoxib is found to be superior to SR 
ibuprofen, its preferential use could be further endorsed by enhancing the scientific rationale 






 Ethics approval and Māori consultation 
 
The study received approval from the Health and Disability Ethics Committee (Appendix 1) 
and was registered with the Australian New Zealand Clinical Trials Registry (Appendix 2). 
Following the University of Otago’s Policy for Research, consultation with Māori was entered 
into with the Ngāi Tahu Research Consultation Committee (Appendix 3). 
 
 Study design 
 





4.2.1.1 Sequence generation 
 
Simple, unrestricted randomisation method was used to allocate participants to either the SR 
ibuprofen group or the etoricoxib group. The allocation sequence was generated by the author 
after consulting a biostatistician, using the Microsoft Excel’s random number generator 
function. The randomisation sequence was then provided to the clinical trials pharmacist based 
at the Dunedin Public Hospital. The copy of the sequence was deleted so that the author had 
no access to it. The off-site pharmacist was the only individual who retained this randomisation 
sequence. 
 
4.2.1.2 Allocation concealment 
 
As and when participants were enrolled, the hospital pharmacist followed the chronological 
order of prescriptions presented, and randomly assigned each participant to one of two parallel 
groups according to the randomisation sequence. The SR ibuprofen and etoricoxib capsules 




the author in sealed, opaque brown envelopes. Each envelope was labelled with the name and 
National Health Index number of the participant to ensure accurate dispensing. Each envelope 
was dispensed to the corresponding participant a day before the surgery and was opened only 




The hospital pharmacist was the only non-blinded person involved in the study. The 
participants, author, research supervisors, and all auxiliaries (dental assistants, registered 
nurses, receptionists, referring dentists) were blinded to the intervention assignment. Blinding 




 Location and setting of the study 
 
Participant recruitment, surgery, and follow-up were completed in the Oral Surgery Unit at the 
School of Dentistry, University of Otago. 
 
 Sample size determination 
 
Assuming an α value of 0.05 and 80% power to detect an anticipated effect size of 0.5, the 
estimated number of participants per group was 64 (Cohen, 1992) necessitating a minimum of 
128 participants. A total of 150 participants were recruited to allow for any dropouts or 
withdrawals from the study. 
 
 Study sample 
 
Participants were recruited from a pool of patients who attended the Primary Care Unit at the 
School of Dentistry, University of Otago, reporting symptoms related to impacted third molars 
or were referred by a dental or medical practitioner for surgical consultation on therapeutic 
reasons (for example, orthodontics and pre-orthognathic surgery). All staff clinicians were 




inclusion criteria. Selected patients were then provided with an initial briefing on the research 
study and those who showed interest were invited to meet the author for a detailed surgical 
consultation. All patients were assured that participation in the study was entirely voluntary 
and refusal to participate would not adversely impact their treatment. 
 
 Eligibility criteria 
 
4.3.4.1 Inclusion criteria 
 
The inclusion criteria for participation included that the patient was: 
1. Deemed capable of providing informed consent to undergo surgical removal of third 
molar teeth under intravenous (IV) sedation with LA; 
2. Deemed to have understood that participation in the study was completely voluntary; 
3. In the age group between 18 and 35 years; 
4. Required removal of at least two impacted mandibular third molars, with or without 
removal of maxillary third molar/s for therapeutic reasons; 
5. Needed bone removal and/or tooth sectioning for extraction of the mandibular third 
molars; and 
6. Deemed fit (American Society of Anaesthesiologist (ASA) physical status 
classification 1 or 2) for outpatient third molar surgery under IV sedation with LA. 
 
4.3.4.2 Exclusion criteria 
 
Patients with any of the following were considered not eligible for participation in the study: 
1. Patients who refused to participate in the study and/or unable to attend follow-up 
appointments; 
2. Patients who were deemed incompetent to provide informed consent; 
3. Patients under the age of 18 years or over 35 years of age; 
4. Patients who preferred to undergo third molar surgery under LA or GA; 
5. Patients who used any analgesics within 48 hours preoperatively; 
6. Patients who had signs and symptoms of local and/or systemic infection; 





8. Patients who refused to remove facial hair which may have impacted the accuracy of 
3D facial photographs; 
9. Patients who needed to drive a motor vehicle or operate machinery on the same day of 
the surgery; or  
10. Patients who had any of the following: 
a. Any significant systemic disease/s classified as ASA 3, 4, or 5 
b. Bodyweight greater than 120kg 
c. Pregnant or lactating mothers 
d. A diagnosis of cardiovascular disease 
e. Respiratory depression 
f. Chronic obstructive pulmonary disease 
g. NSAID-triggered asthma 
h. Metabolic diseases 
i. Active or history of gastrointestinal bleeding or ulceration 
j. Hepatic impairment 
k. Renal impairment 
l. Bleeding disorder 
m. Bone disorders 
n. Patients with known psychological or psychiatric conditions 
o. Patients on therapeutic anticoagulation 
p. Patients on bisphosphonates 
q. Patients taking long-term benzodiazepines, opioids, psychotropic drugs, or liver 
enzyme induction agents and/or medications 
r. Known history of hypersensitivity to benzodiazepines, etoricoxib, ibuprofen, 
and codeine phosphate 
s. Opioid and illicit drug addiction 
t. Alcoholism 
Also excluded were patients who had third molars with any of the following: 
a. Associated pathology; 
b. Third molar/s requiring coronectomy; 
c. Third molar surgery deemed to have a significant risk for mandibular fracture; 
d. Maxillary third molar/s with a significant risk of creating oro-antral 




e. Oral surgery requiring more than four third molars extracted at the same sitting. 
 
 Obtaining patient consent for participation 
 
The surgical consultation was completed by the author at an outpatient clinic. The clinical 
assessment during this appointment included: current and past health status; current third molar 
status (pain, associated pathologies, postoperative complication risks); the anticipated level of 
third molar surgical difficulty; and the patient’s preference for anaesthesia (LA, IV, or GA). 
Patients were screened through the inclusion and exclusion criteria of the study to identify 
potentially eligible participants. 
 
Patients who met the eligibility criteria were then invited to participate in the study. They were 
provided with a detailed explanation of the nature and purpose of the study, participant rights 
and responsibilities, and the potential benefits and risks involved. Patients who were interested 
in participating were provided with the research information sheet (Appendix 4). They were 
invited to ask questions for clarification and were encouraged to discuss with their family and 
friends if needed. Those who chose to participate then completed the written consent form for 
enrolment in the study. 
 
 Assurance to participants 
 
All participants were informed of the following assurances before their enrolment in the study: 
1. The study was approved by the New Zealand Health and Disability Ethics Committee 
and registered with the Australian New Zealand Clinical Trials Registry. 
2. All the perioperative drugs will be provided at doses approved by the New Zealand 
Medicines and Medical Devices Safety Authority. The perioperative drugs are: SR 
ibuprofen or etoricoxib; dexamethasone; midazolam; paracetamol; ibuprofen; codeine 
phosphate; and chlorhexidine gluconate. 
3. Participants will be informed of potential side-effects associated with the above 
perioperative drugs. 
4. Participants will be informed of how and when to take their study medication and 
postoperative analgesics. 




6. Participant identifiers will not appear in the thesis nor in any future scientific 
publications which may arise from the research, unless written consent is formally 
obtained for the use of photographs for publication in a scientific journal and/or 
presentation at a conference. 
7. The study data will be retained in a de-identified format and stored securely at the 
University of Otago for 10 years as per University of Otago research policy. 
8. Participants may withdraw from the study at any time with no disadvantage to their 
surgical care and management. 
9. Participants will have access for comprehensive emergency care around the clock 
following surgical removal of their third molars. They will be provided with details for 
contacting the on-call team for dental emergencies at the School of Dentistry or the 
Dunedin Public Hospital as appropriate. The on-call team will be instructed to contact 
the author as appropriate. Phone numbers of the oral surgery team and Dunedin Public 
Hospital are stated on the “Participant Information Sheet” (Appendix 4). 
 
 Participant responsibilities 
 
By consenting to participate in the study, the participant agreed to: 
1. Take the recommended study medication 2 hours before third molar surgery; 
2. Attend the surgical appointment and, 
a. Complete a preoperative participant questionnaire (Appendix 5); 
b. Rate their preoperative pain intensity (Appendix 6); 
c. Have preoperative 3D facial photographs taken and maximum mouth opening 
measured (Appendix 7); and 
d. Undergo third molar surgery under IV sedation with LA 
3. Rate and record the pain intensity in the pain diary every 3 hours, while awake, during 
the first 48-hour postoperative period and complete the questionnaires on the use of 
rescue analgesia (Appendix 8); and 
4. Attend review appointment at 48 hours (48 h) postoperatively to: 
a. Return their completed pain diary; 
b. Complete a postoperative participant questionnaire (Appendix 9); 
c. Have postoperative 3D facial photographs taken and maximum mouth opening 





 Participation incentives 
 
The study medications (SR ibuprofen and etoricoxib) and chlorhexidine gluconate mouthwash 
were provided to participants free of charge. 
 
 Treatment groups 
 
Participants allocated to the SR ibuprofen group received SR ibuprofen 1.6g. Participants 
allocated to the etoricoxib group received etoricoxib 120mg. The study medication was self-
administered orally by the participant 2 hours before third molar surgery. 
 
SR ibuprofen 1.6g and etoricoxib 120mg were specifically prepared, each across 4 capsules by 
an independent compounding pharmacy in Auckland. Because the dose and density of the SR 
ibuprofen 1.6g were too large for a single capsule, it had to be divided across 4 capsules (that 
is, each capsule contained 400mg of SR ibuprofen). The etoricoxib 120mg was, therefore, 
prepared over 4 capsules too (that is, each capsule contained 30mg of etoricoxib) to ensure it 
appeared identical to SR ibuprofen. Both medications were packed into bottles containing 4 
capsules each for dispensing to individual participants. All medications had 1-year expiry from 
the date of preparation. They were received in a single consignment by clinical trials pharmacist 
at the Dunedin Public Hospital for random assignment as participants were recruited. Each 
bottle was labelled “SR ibuprofen 1.6g or etoricoxib 120mg as per study protocol”. The bottles 
remained concealed from the author for blinding, by being packed into sealed, opaque brown 
envelopes labelled with participant identifiers. Each sealed envelope containing the medication 
was dispensed to the corresponding participant a day before their surgery, with specific 
instructions on how and when to administer the capsules. 
 
 Study procedure 
 
All participants were asked to take their study medication with a glass of water 2 hours before 
third molar surgery. A text reminder was sent to the participant’s mobile phone 15 minutes 
before the allocated time of drug administration. Upon arrival at the Oral Surgery Unit, all 




pain intensity. A 3D facial photograph and maximum mouth opening were taken preoperatively. 
Following the surgery, all participants were asked to rate their pain intensity in a pain diary 
every 3 hours, while awake, for the first 48 hours and complete the questionnaires on the use 
of rescue analgesia. The pain diary was to begin 3 hours after the first mucosal incision was 
made; the starting time was specified in the diary before discharging participants. Participants 
were instructed to adhere to the postoperative analgesic regimen: 
1. Paracetamol 1g four times daily for the first 2 days, then as required; 
2. Ibuprofen 400mg three times daily (to start 18 hours after the study medication 
administration) for the first 2 days, then as required; and 
3. Codeine phosphate 30mg-60mg four times daily as required (that is, rescue analgesia). 
 
All participants were given a 200ml bottle of 0.2% chlorhexidine gluconate mouthwash to use 
three times daily for 7 days, commencing 24 hours postoperatively. On a 48 h review, the pain 
diary was collected and the 3D photograph and maximum mouth opening were taken again. A 
postoperative participant questionnaire was also completed. At the School of Dentistry, there 
is an ethical obligation to review all surgical patients 2 weeks postoperatively. Although not 
part of the protocol of the present study, data was collected on the number of participants who 
reported a significant residual pain at week 2 review. The summarised study protocol is 





Figure 5. Flowchart of the study protocol 
 
  Patient referred to the Oral Surgery Unit for third molar surgery 
Appointment 1: surgical consultation 
• Eligibility criteria met 
• Participation consent obtained 
Appointment 2: surgical appointment 
Pre-emptive analgesia groups: 
• SR ibuprofen 1.6g 2 hours before surgery 
or 
• Etoricoxib 120mg 2 hours before surgery 
 
1. Preoperative questionnaire 
2. Preoperative pain intensity, facial photograph, and maximum mouth opening 
recorded 
3. Third molar surgery under IV sedation with LA 
4. Pain diary provided 
Appointment 3: 48 h postoperative review 
1. Pain diary collected 
2. Postoperative questionnaire 
3. Postoperative facial photograph and maximum mouth opening recorded 
4. End of participant commitment 
Week 2 postoperative review (as per School of Dentistry’s minor oral surgery 
postoperative review protocol) 
1. Suture removal 




All patients underwent surgical removal of third molars under IV sedation with LA at the 
School of Dentistry, University of Otago. All surgical procedures were performed by the author, 
observing an aseptic surgical technique aligned with the Dental Council of New Zealand’s 
recommended standards for performing minor oral surgery. The perioperative drugs 
administered by the author were: 
1. Dexamethasone 8mg/2ml; 
2. Midazolam 5mg/5ml titrated to effect in 1mg increments; and 
3. Lignocaine with 2% with adrenaline 1:80,000 for inferior alveolar nerve block and 
infiltration in the buccal sulcus near mandibular third molars. 
 
The adequacy of LA was confirmed before making mucosal incisions. For mandibular third 
molars, this was verified by the participant’s reported, perceived numbness of the lower lip and 
mucosa of the surgical site. The surgical technique was standardised for all participants: 
1. A buccal envelope flap with lingual flap protection as appropriate; 
2. Removal of the overlying bone and buccal guttering, with or without tooth sectioning; 
3. Tooth elevation and delivery; 
4. Saline irrigation; and 
5. Re-approximation of the flap using a resorbable polyglactin suture. 
 
Participants were monitored throughout the perioperative period by a registered nurse trained 
in IV sedation. They were discharged with a prescription for paracetamol, ibuprofen, and 
codeine phosphate. 
 
 Data collection 
 
 Measurement of pain 
 
The intensity of pain was measured using a 100mm visual analogue scale (VAS). Participants 
were asked to rate third molar-related pain just before the surgery (baseline pain level) and 
every 3 hours, while awake, for the first 48 hours post-surgery. During the 48 h review 
appointment, participants rated their overall perception of pain using a verbal rating scale 
(VRS). The VRS comprised a 5-point Likert scale (no pain, mild pain, moderate pain, severe 




between the end of the surgery and the first use of rescue analgesia and the total number of 
rescue analgesics consumed per day. Other methods to evaluate the participants’ postoperative 
pain experience included a postoperative questionnaire which covered the following 
parameters: the adequacy of postoperative analgesic regimen in pain control; the need for 
additional analgesic agent/s other than those prescribed by the author; and whether a medical 
GP review was required for poorly controlled pain. 
 
 Measurement of swelling 
 
The extent of postoperative facial swelling was determined by the facial volumetric differences 
observed between the pre- and postoperative 3D photographs of the participants. The Version 
2.5.406 of 3dMD (2015a) was used to take the photographs just before third molar surgery and 
on 48 h postoperative review appointment. 
 
Before image acquisition, all participants were asked to pull away from the forehead, ears, and 
mandible any hair that may otherwise have compromised the surface data and interfere with 
the accuracy of image analysis. Male participants were requested to be clean-shaven to 
maximise the image quality. Eyeglasses and shirts with high collars or hoods that obscured the 
surface anatomy were removed. Participants were instructed to maintain a neutral facial 
expression with the mouth closed during image capture. 
 
The 3D images were analysed using the Version 2.6.0.1 of 3dMD (2019) analysis software. 
The pre- and postoperative images were reoriented separately so that their new 3D x, y, z 
coordinate systems were standardised for analysis. All images were refined to maximise the 
accuracy during the superimposition process. Superimposition involved registering the pre- 
and postoperative images together. The two images were manually aligned by registering the 
stable facial surface areas, such as the glabella and the bridge of the nose. This was followed 
by the software’s automatic registration feature to fine-tune the alignment. As per the analysis 
manual, the precision of the superimposition was defined as a variation of less than 0.5mm 
between the pre- and postoperative images in the selected reference surfaces (3dMD, 2015b). 
The volume comparison between the superimposed images was then achieved by selecting a 
4-point soft tissue landmark to map the surface area of interest: the tragus of the ear, soft tissue 




volumetric difference was measured three times consecutively on each side of the face and the 
three values were averaged. This average value from each side of the face was then added 









This figure shows the preoperative image superimposed with the postoperative image. The 
postoperative image is set at 50% translucency for a better visualisation of the extent of 






Figure 7. Facial swelling on postoperative day 2 - (a) left oblique and (b) right oblique 
 
 
Arrows represent the increased facial volume of the postoperative image set at 50% 








The selected area for volume comparison is mapped by a 4-point soft tissue landmark: the 
tragus of the ear, soft tissue gonion, cheilion, and the parasymphysis (defined as a vertical  line 




 Measurement of trismus 
 
Trismus was assessed using a metal ruler to measure the distance between the mesio-incisal 
edges of the right maxillary and mandibular central incisor teeth at the maximal mouth opening. 
The mouth opening was assessed just before third molar surgery and on 48 h review 
appointment. 
 
 Other information 
 
The preoperative participant questionnaire collected baseline data on sociodemographic 
characteristics (age, sex, ethnicity, education, occupation), self-reported oral health status, 
current smoking use, history of third molar pain, and the Dental Anxiety Scale (Corah, 1969). 
The impact of pre-emptive analgesia on oral-health-related quality of life was assessed by the 
Oral Health Impact Profile (OHIP-14) (Slade, 1997). All participants were asked to complete 
OHIP-14 questionnaire twice; first, immediately before the surgery and then at 48 h review 
appointment. Furthermore, following clinical details were recorded for each participant: 
1. The type of third molar impaction according to the Winter’s classification (Winter, 
1926) and Pell and Gregory classification (Pell & Gregory, 1933); 
2. The number of maxillary third molars extracted; 
3. The surgical time; and 
4. Any perioperative complications encountered. 
 
Information regarding adverse events (nausea, vomiting, stomach pain, diarrhoea, any other 
symptoms experienced) was collected along with their frequency, severity, and impact on daily 
activities during the 48-hour postoperative period (Appendix 11). Additionally, participants 
who reported significant residual pain at 2 weeks following the surgery was recorded. 
 
 Statistical methods 
 
Statistical analysis used IBM SPSS Statistics (Version 26). Baseline characteristics and 
categorical data of the two study groups were compared using Chi-square tests. The summary 
data on VAS, the use of rescue analgesia, swelling, trismus, and oral-health-related quality of 




sizes were also calculated for these parameters. Multiple linear regression was conducted at 
various postoperative time points to examine the association between the VAS and the 
medication group, controlling for confounders that may affect postoperative pain. A P value 
less than 0.05 was statistically significant. 
 
 Funding and payment for treatment 
 
This study was funded by the Sir John Walsh Research Institute Doctor of Clinical Dentistry 
Research Grant. All participants were invoiced for their surgical treatment according to the 







This chapter presents the findings of the study. It will begin with a description of the participant 
flow through each stage of the study and their baseline preoperative characteristics. This will 
be followed by the core postoperative findings and ancillary analyses. 
 
 Participant flow 
 
A total of 170 patients (study population) who presented to the School of Dentistry for third 
molar surgical consultation were assessed for eligibility to participate in the study. Of these, 
11 (6.5%) did not meet eligibility criteria and 9 (5.3%) declined to participate due to 
commitments that precluded attending a review at 48-hour postoperative time point (48 h). 
Accordingly, a total of 150 participants were enrolled in the study (study sample, n=150) and 
subsequently assigned to either the SR ibuprofen or the etoricoxib group using the 
randomisation sequence. The random allocation process generated 75 participants in each 
treatment group. 
 
All participants underwent third molar surgery under IV sedation. However, a total of 15 
participants (7 from the SR ibuprofen group, 8 from the etoricoxib group) were excluded, as 
described in the CONSORT flowchart (Figure 9). Despite this exclusion, the total of 135 
participants with complete data still exceeded the minimum sample size of 128 needed for 













 Protocol deviations 
 
The nature of the 3-hourly postoperative visual analogue scale (VAS) recording meant that 
there was an inherently poor response at certain time points. Excellent response rates were 
found at 6 hours, 9 hours, between 24 and 30 hours, and 48 hours. Accordingly, VAS analysis 
was focused on those specific postoperative time points. 
 
 Study period (recruitment and follow-up) 
 
Participant recruitment, surgery, and follow-up took place at the School of Dentistry between 
November 2018 and December 2019. The recruitment commenced in November 2018 and 
closed in October 2019. Surgical procedures were performed between February 2019 and 
December 2019, with the follow-up appointment for each participant completed at 48-hour 





 Baseline data 
 
Table 7 shows data on sociodemographic features, self-oral care, and smoking habits of the 
participants by the group. 
 
Table 7. Sociodemographic characteristics, self-care and self-reported oral health by group 
(brackets contain column percentages unless otherwise indicated) 
 
 Group Both combined P value 
 Etoricoxib SR ibuprofen   
     
Sex     
Male 22  (29.3) 29  (38.7) 51   (34.0) 0.23 
Female 53  (70.7) 46  (61.3) 99   (66.0)  
Age group (years)    0.40 
18-20 25  (33.3) 19  (25.3) 44   (29.3)  
21-24 32  (42.7) 40  (53.3) 72   (48.0)  
25+ 18  (24.0) 16  (21.3) 34   (22.7)  
Mean age (SD) 22.3 (3.5) 22.9 (3.6) 22.6  (3.6) 0.34 
Ethnicity    0.45 
Pākeha 58  (77.3) 54  (72.0) 112 (74.7)  
Other 17  (22.7) 21  (28.0) 38   (25.3)  
Tertiary education    0.51 
No 37  (49.3) 33  (44.0) 70   (46.7)  
Yes 38  (50.7) 42  (56.0) 80   (53.3)  
Brush more than 
once/day 
   0.69 
No 15  (20.0) 17  (22.7) 32   (21.3)  
Yes 60  (80.0) 58  (77.3) 118 (78.7)  
Current smoker    0.41 
No 69  (92.0) 66  (88.0) 135 (90.0)  
Yes   6    (8.0)   9  (12.0) 15   (10.0)  
     
All combineda 75  (50.0) 75  (50.0) 150 (100.0)  
     
a Brackets contain row percentages 
 
Both groups had a mean age of early twenties, female predominance, and a higher proportion 
of New Zealand Europeans. Most participants were non-smokers and brushed their teeth more 
than once a day. More than half the participants in both groups had attained tertiary education. 
There were no statistically significant differences in sociodemographic and self-oral care 




Over 80% of participants experienced third molar related pain at some point in the 4 weeks 
preceding third molar surgery; most reporting moderately intense pain (Table 8). Preoperative 
VAS scores for third molar pain and maximum mouth opening (interincisal distance) in both 
groups were comparable. 
 
Table 8. Preoperative third molar pain and maximum mouth opening (brackets contain column 
percentages unless otherwise indicated) 
 
 Group Both combined P value 
 Etoricoxib SR ibuprofen   
     
History of third molar 
pain/discomfort 
   0.62 
No 10  (13.3)   8  (10.7)    18   (12.0)  
Yes 65  (86.7) 67  (89.3)  132   (88.0)  
Third molar 
pain/discomfort in the 
last 4 weeks 
   0.52 
Never 18  (24.0) 15  (20.0)     33   (22.0)  
Occasionally 26  (34.7) 24  (32.0)     50   (33.3)  
Sometimes 16  (21.3) 12  (16.0)     28   (18.7)  
Often 13  (17.3) 22  (29.3)     35   (23.3)  
Always   2    (2.7)   2    (2.7)      4     (2.7)  
Intensity of third 
molar pain/discomfort 
   0.60 
Mild 21  (28.0) 27  (36.0)     48   (32.0)  
Moderate 33  (44.0) 32  (42.7)     65   (43.3)  
Severe   7    (9.3)   7    (9.3)     14     (9.3)  
Not applicable 14  (18.7)   9  (12.0)     23   (15.3)  
     
Mean VASa (SD)   8    (14)   6    (11)    7     (13) 0.87 
Maximum mouth 
openingb (SD) 
47.5 (6.6) 48.0 (6.7)   47.7  (6.6) 0.67 
     
a Visual analogue scale measured in millimetres 





The mean preoperative OHIP-14 and dental anxiety scale (DAS) scores were similar in both 
groups (Table 9). 
 
Table 9. Preoperative oral health impact profile and dental anxiety scale scores by group 
(brackets contain standard deviations unless otherwise indicated) 
 
 Group Both combined P value 
 Etoricoxib SR ibuprofen   
     
Mean OHIP-14 9.4 (7.4) 11.3   (8.8) 10.4   (8.1) 0.16 
Mean DAS 9.6 (4.0)   9.0   (3.8)   9.3   (3.9) 0.34 






Table 10. Number and type of mandibular impactions (Pell and Gregory classification) and 
angulation type (Winter’s classification) by group (brackets contain column 
percentages unless otherwise indicated) 
 
 Group Both combined P value 
 Etoricoxib SR ibuprofen   
     
Tooth 38    0.87 
1a   1   (1.3)   0   (0.0)   1   (0.7)  
1b   2   (2.7)   1   (1.3)   3   (2.0)  
1c   0   (0.0)   0   (0.0)   0   (0.0)  
2a 22 (29.3) 26 (34.7) 48 (32.0)  
2b 12 (16.0) 13 (17.3) 25 (16.7)  
2c   0   (0.0)   0   (0.0)   0   (0.0)  
3a 21 (28.0) 20 (26.7) 41 (27.3)  
3b 17 (22.7) 15 (20.0) 32 (21.3)  
3c   0   (0.0)   0   (0.0)   0   (0.0)  
Angulation type    0.97 
Horizontal 18 (24.0) 19 (25.3) 37 (24.7)  
Mesial 20 (26.7) 20 (26.7) 40 (26.7)  
Vertical 12 (16.0) 10 (13.3) 22 (14.7)  
Distal 25 (33.3) 26 (34.7) 51 (34.0)  
Transverse   0   (0.0)   0   (0.0)   0   (0.0)  
     
Tooth 48    0.06 
1a   0   (0.0)   0   (0.0)   0   (0.0)  
1b   2   (2.7)   1   (1.3)   3   (2.0)  
1c   0   (0.0)   0   (0.0)   0   (0.0)  
2a 32 (42.7) 34 (45.3) 66 (44.0)  
2b 14 (18.7) 23 (30.7) 37 (24.7)  
2c   0   (0.0)   0   (0.0)   0   (0.0)  
3a 12 (16.0) 13 (17.3) 25 (16.7)  
3b 15 (20.0)   4   (5.3) 19 (12.7)  
3c   0   (0.0)   0   (0.0)   0   (0.0)  
Angulation type    0.99 
Horizontal 21 (28.0) 20 (26.7) 41 (27.3)  
Mesial 25 (33.3) 26 (34.7) 51 (34.0)  
Vertical 10 (13.3) 11 (14.7) 21 (14.0)  
Distal 19 (25.3) 18 (24.0) 37 (24.7)  
Transverse   0   (0.0)   0   (0.0)   0   (0.0)  
     
 
Table 10 presents a summary of mandibular third molar impaction types by the two groups. 
Distoangular impaction was the most common in tooth 38, followed by mesial and horizontal 




horizontal and distal (Winter, 1926). The most common Pell and Gregory impaction type (Pell 
& Gregory, 1933) was 2a in teeth 38 and 48, followed by 3a in tooth 38 and 2b in tooth 48. 
There were no statistically significant differences between the two groups. 
 
Overall, the above data demonstrate that the baseline characteristics of the participants in the 
SR ibuprofen and etoricoxib groups (including third molar impaction types and history of third 









Table 11. Mean postoperative VAS by group at different time points (brackets contain standard 
deviations unless otherwise indicated) 
 
 Etoricoxib SR ibuprofen   
     
 Mean 
VASa 
95% CI Mean 
VAS 
95% CI Effect 
size 
P value 









         
Baseline   7 (11)   4   9   6 (10)   4   9   
6h 33 (23) 27 39 34 (23) 28 40 0.04 0.79 
9h 28 (20) 23 33 35 (26) 28 41 0.30 0.09 
24h 29 (22) 24 35 33 (26) 27 39 0.17 0.39 
27h 27 (22) 22 33 29 (24) 23 34 0.09 0.74 
30h 27 (21) 21 32 29 (22) 24 35 0.09 0.45 
48h 32 (24) 26 39 35 (23) 29 41 0.13 0.58 
        
a Visual analogue scale measured in millimetres 
 
Table 11 shows the mean VAS score at the 6-, 9-, 24-, 27-, 30-, and 48-hour postoperative time 
points. Overall, a slightly higher VAS score was noted in the SR ibuprofen group than the 
etoricoxib group throughout the postoperative period (Figure 10). The intensity of pain at 48 
hours was similar to that reported at 6 hours postoperatively in both medication groups. The 
effect sizes were small throughout these time points; that is, the magnitudes of the difference 







Figure 10. Mean VAS (mm) in the etoricoxib and SR ibuprofen groups recorded at specific 








 Postoperative rescue analgesia 
 
Just over half of the participants in both groups required rescue analgesia during the 48-hour 
postoperative period. The mean time to first rescue analgesia was 5 hours postoperatively and 
the total number of rescue analgesics consumed was comparable between the two groups with 
no statistically significant difference (Table 12). 
 
Table 12. Postoperative rescue analgesia requirement by group (brackets contain standard 
deviations unless otherwise indicated) 
 





 Etoricoxib SR ibuprofen    
      
Number of patients who 
used rescue analgesiaa 
 40  (59.7)   39  (57.4)   79  (58.5)  0.78 
Mean time to rescue 
analgesia requirementb 
   5.0 (3.1)     5.3 (3.9)     5.2 (3.5) 0.10 0.66 
Mean total number of 
rescue analgesics 
consumedc 
   3.4 (3.6)     4.4 (4.4)     3.9 (4.1) 0.26 0.14 
      
a Brackets contain column percentages 
b Measured in hours 






 Swelling and mouth opening 
 
The mean facial volumetric differences in both groups were comparable (Table 13). The effect 
size was extremely small for facial swelling, with no statistically significant difference between 
the two groups. The mean maximum mouth opening had reduced by one-third in both groups 
by the second postoperative day. The effect sizes of the difference between the preoperative 
and 48 h for both medication groups were large. Yet, there was no statistically significant 
difference between two groups. 
 
Table 13. Mean facial volumetric difference and maximum mouth opening by group (brackets 
contain standard deviations unless otherwise indicated) 
 
 Group Effect size P value 
 Etoricoxib SR ibuprofen   
     
Mean volumetric 
differencea  
    15.3 (10.3)      15.8 (10.4) 0.05 0.80 
Mean maximum mouth 
openingb 
    
Preoperative     47.6   (6.8)      47.7   (6.8)  0.91 
48 h     32.5   (9.5)      32.3   (8.9) 
 
0.86 
Effect size       2.2   (large)        2.3   (large)   
     
a Volumetric difference (0-48 h) measured in cubic centimetres 





 Multivariate modelling 
 
Multiple linear regression was conducted at 6-, 9-, 24-, 27-, 30-, and 48-hour postoperative 
time points to examine the relationship between the postoperative VAS score and the 
medication group, controlling for relevant explanatory (independent) variables which may 
affect postoperative pain (Tables 14 to 19). 
 
At all of the above stated postoperative time points, the regression models showed that there 
was insufficient evidence to conclude that medication group membership was a significant 
predictor of postoperative pain score (P>0.05). However, it is noteworthy that pain scores were 
consistently higher in the SR ibuprofen group throughout the postoperative period. 
 
The regression models showed a positive association between the baseline and the 
postoperative VAS scores at all of the time points. The highest regression coefficient was 0.85 
at 9 hours following the surgery (P<0.001), with the 95% confidence interval ranging from 
0.50 to 1.21; that is, the model predicted that, for a 1cm higher preoperative VAS, the 
postoperative VAS was higher by 0.50cm to 1.21cm, holding all other variables constant (Table 
15). 
 
Age was negatively associated with the mean 30-hour postoperative VAS score, with a 
regression coefficient of -1.11 and P value of 0.04 (Table 18). Excluding this time point, there 
was no apparent association between postoperative pain and age. Furthermore, sex, total 
surgical time, additional removal of maxillary third molar/s, and primary closure of mandibular 










95% Confidence interval P value 
  Lower bound Upper bound  
     
SR ibuprofen group   1.77 -5.93 9.46 0.65 
Mean preoperative VAS   0.70  0.34 1.06 <0.001 
Age -0.92 -2.07 0.24 0.12 
Female sex -0.88 -9.91 8.15 0.85 
Surgical time taken -0.04 -0.30 0.23 0.79 
Surgical removal of 38, 48    
and at least one 
maxillary third molar 
-1.61 -9.88 6.65 0.70 
Primary closure of at least 
one mandibular third 
molar 
-3.79 -12.09 4.51 0.37 










95% Confidence interval P value 
  Lower bound Upper bound  
     
SR ibuprofen group   6.98 -0.54 14.51 0.07 
Mean preoperative VAS   0.85  0.50 1.21 <0.001 
Age -0.92 -2.09 0.25 0.12 
Female sex -2.83 -11.60 5.93 0.52 
Surgical time taken -0.14 -0.39 0.12 0.30 
Surgical removal of 38, 48 
and at least one 
maxillary third molar 
-1.13 -9.22 6.95 0.78 
Primary closure of at least 
one mandibular third 
molar 
-1.15 -9.37 7.06 0.78 











95% Confidence interval P value 
  Lower bound Upper bound  
     
SR ibuprofen group  4.13 -3.83 12.10 0.31 
Mean preoperative VAS  0.76  0.39 1.13 <0.001 
Age -0.98 -2.16 0.19 0.10 
Female sex  1.96 -7.36 11.27 0.68 
Surgical time taken  0.02 -0.25 0.28 0.89 
Surgical removal of 38, 48 
and at least one 
maxillary third molar 
 3.26 -5.28 11.80 0.45 
Primary closure of at least 
one mandibular third 
molar 
-7.75 -16.30 0.80 0.08 










95% Confidence interval P value 
  Lower bound Upper bound  
     
SR ibuprofen group  1.34 -6.11 8.79 0.72 
Mean preoperative VAS  0.76  0.41 1.11 <0.001 
Age -0.99 -2.09 0.11 0.08 
Female sex -0.86 -9.62 7.89 0.85 
Surgical time taken -0.17 -0.42 0.09 0.19 
Surgical removal of 38, 48 
and at least one 
maxillary third molar 
-1.99 -9.97 6.00 0.62 
Primary closure of at least 
one mandibular third 
molar 
-4.64 -12.65 3.38 0.25 











95% Confidence interval P value 
  Lower bound Upper bound  
     
SR ibuprofen group   3.45 -3.56  10.45 0.33 
Mean preoperative VAS   0.62  0.29  0.94 <0.001 
Age -1.11 -2.16 -0.07 0.04 
Female sex -0.77 -8.96  7.43 0.85 
Surgical time taken -0.05 -0.29  0.19 0.67 
Surgical removal of 38, 48 
and at least one 
maxillary third molar 
-1.12 -8.55  6.31 0.77 
Primary closure of at least 
one mandibular third 
molar 
-6.15 -13.71 1.41 0.11 









95% Confidence interval P value 
  Lower bound Upper bound  
     
SR ibuprofen group   2.43 -5.71 10.56 0.56 
Mean preoperative VAS   0.64  0.24 1.03 <0.001 
Age -0.98 -2.19 0.22 0.11 
Female sex -0.38 -10.01 9.25 0.94 
Surgical time taken -0.03 -0.30 0.25 0.86 
Surgical removal of 38, 48 
and at least one 
maxillary third molar 
-1.98 -11.01 7.05 0.67 
Primary closure of at least 
one mandibular third 
molar 
-6.64 -15.45 2.17 0.14 






 Oral-health-related quality of life 
 
OHIP-14 data were collected immediately before surgery and again at the second postoperative 
day review appointment. Table 20 summarises the preoperative and postoperative data. 
 
Table 20. Pre- and postoperative oral health impact profile by group (brackets contain standard 
deviations unless otherwise indicated) 
 
 Group Both combined P value 
 Etoricoxib SR ibuprofen   
     
Mean OHIP-14a     
Preoperative   9.4 (7.4) 11.3 (8.8) 10.4 (8.1) 0.16 
48 h 14.8 (9.2) 16.6 (9.1) 15.7 (9.2) 0.26 
Effect size   0.7 (moderate)   0.6 (moderate)   
Prevalence of 1+ 
impactsb 
    
48 h  42   (62.7)  53   (77.9) 95  (70.4) 0.05 
     
a Oral health impact profile 
b ‘Fairly often’ or ‘very often’; brackets contain column percentages 
 
Third molar surgery negatively impacted the oral-health-related quality of life, irrespective of 
the type of pre-emptive analgesia. Following surgery, OHIP-14 scores increased about 1.5-fold 
in both medication groups. The effect sizes were moderate. Although the postoperative score 
was slightly higher in the SR ibuprofen group, this difference was not statistically significant. 
 
At 48 hours postoperatively, more than half the participants in both groups reported one or 
more OHIP responses ‘fairly often’ or ‘very often.’ An almost significantly greater proportion 
of participants in the SR ibuprofen group reported a severe impact of third molar surgery on 
their quality of life than those in the etoricoxib group. 
 
OHIP-14 subscale scores were analysed to further assess the impact of third molar surgery on 
specific dimensions of participants’ quality of life (Table 21). The postoperative subscale 
scores were higher than the preoperative data in all domains. The highest mean score of 4.6 
(etoricoxib) and 5.0 (SR ibuprofen) was observed in physical pain, followed by psychological 




Overall, this reflects that third molar surgery had the most impact in the domain of pain, along 
with compromised diet and adverse psychological outcomes. 
 
Table 21. Mean preoperative and 48 h postoperative OHIP-14 subscale scores by group 
(brackets contain standard deviations unless otherwise indicated) 
 
 Etoricoxib SR ibuprofen 
 Preoperative     48 h Preoperative     48 h 
     
Functional limitation  0.5 (1.1) 1.2 (1.5) 0.5 (1.2) 1.4 (1.4) 
Physical pain  2.6 (2.1) 4.6 (1.9) 3.3 (2.2) 5.0 (1.6) 
Psychological 
discomfort 
 2.3 (2.4) 2.8 (2.8) 2.6 (2.6) 2.6 (2.6) 
Physical disability  1.1 (1.2) 2.2 (1.8) 1.7 (1.7) 2.9 (2.2) 
Psychological 
disability 
 0.9 (0.9) 1.2 (1.0) 1.1 (1.1) 1.3 (1.0) 
Social disability  1.3 (1.4) 1.8 (1.8) 1.4 (1.5) 2.3 (1.7) 
Handicap  0.7 (1.1) 0.9 (1.2) 0.9 (1.5) 1.1 (1.5) 






 Adverse events profile 
 
Postoperative adverse events are summarised by treatment group in Table 22. 
 
Table 22. Postoperative adverse events by group (brackets contain column percentages unless 
otherwise indicated) 
 
 Group Both combined P value 
 Etoricoxib SR ibuprofen   
     
Nausea  26   (38.8) 20    (29.4)   46   (34.1) 0.25 
Frequency    0.53 
Fairly/very often    5   (19.2)   3    (15.0)     8   (17.4)  
Occasionally  10   (38.5) 11    (55.0)   21   (45.7)  
Hardly ever  11   (42.3)   6    (30.0)   17   (37.0)  
Severity     0.48 
Severe    0     (0.0)   1     (5.0)     1     (2.2)  
Moderate  11   (42.3)   7   (35.0)   18   (39.1)  
Mild  15   (57.7) 12   (60.0)   27   (58.7)  
Effect on daily activities    0.17 
A lot    0     (0.0)   2   (10.0)     2     (4.3)  
Some    7   (26.9)   6   (30.0)   13   (28.3)  
A little  11   (42.3) 10   (50.0)   21   (45.7)  
Not at all    8   (30.8)   2   (10.0)   10   (21.7)  
     
Vomiting    2     (3.0)   2     (2.9)     4     (3.0) 0.99 
Frequency    1.00 
Fairly/very often    0     (0.0)   0     (0.0)     0     (0.0)  
Occasionally    1   (50.0)   1   (50.0)     2   (50.0)  
Hardly ever    1   (50.0)   1   (50.0)     2   (50.0)  
Severity     
Severe    0     (0.0)   0     (0.0)     0     (0.0)  
Moderate    0     (0.0)   0     (0.0)     0     (0.0)  
Mild    2 (100.0)   2 (100.0)     4 (100.0)  
Effect on daily activities     
A lot    0     (0.0)   0     (0.0)     0     (0.0)  
Some    0     (0.0)   0     (0.0)     0     (0.0)  
A little    2 (100.0)   2 (100.0)     4 (100.0)  
Not at all    0     (0.0)   0     (0.0)     0     (0.0)  
     
Stomach pain  13   (19.4) 12   (17.6)   25   (18.5) 0.79 
Frequency    0.62 
Fairly/very often    3   (23.1)   2   (16.7)     5   (20.0)  
Occasionally    6   (46.2)   4   (33.3)   10   (40.0)  
Hardly ever 
 





Severity    0.76 
Severe    1     (7.7)   0     (0.0)     1     (4.0)  
Moderate    3   (23.1)   4   (33.3)     7   (28.0)  
Mild    8   (61.5)   7   (58.3)   15   (60.0)  
Not applicable    1     (7.7)   1     (8.3)     2     (8.0)  
Effect on daily activities    0.12 
A lot    1     (7.7)   0     (0.0)     1     (4.0)  
Some    3   (23.1)   2   (16.7)     5   (20.0)  
A little    4   (30.8)   9   (75.0)   13   (52.0)  
Not at all    5   (38.5)   1     (8.3)     6   (24.0)  
     
Diarrhoea    3     (4.5)   4     (5.9)     7     (5.2) 0.71 
Frequency    0.46 
Fairly/very often    0     (0.0)   1   (25.0)     1   (14.3)  
Occasionally    2   (66.7)   1   (25.0)     3   (42.9)  
Hardly ever    1   (33.3)   2   (50.0)     3   (42.9)  
Severity    0.66 
Severe    0     (0.0)   0     (0.0)     0     (0.0)  
Moderate    1   (33.3)   2   (50.0)     3   (42.9)  
Mild    2   (66.7)   2   (50.0)     4   (57.1)  
Effect on daily activities    0.12 
A lot    0     (0.0)   0     (0.0)     0     (0.0)  
Some    1   (33.3)   2   (50.0)     3   (42.9)  
A little    2   (66.7)   0     (0.0)     2   (28.6)  
Not at all    0     (0.0)   2   (50.0)     2   (28.6)  
     
 
About one-third of the participants experienced nausea and just under a fifth of the participants 
experienced stomach pain. Although nausea was slightly more prevalent and of moderate 
severity in the etoricoxib group, there was no statistically significant difference between the 
two treatment groups. The number of participants who had stomach pain did not differ between 
the groups. The etoricoxib group reported more frequent episodes of stomach pain than the SR 
ibuprofen group, as well as its greater effect on daily activities. However, there were no 
significant differences between the groups. Only four participants reported postoperative 
vomiting while seven participants reported diarrhoea. Other self-reported adverse events 





Table 23. Adverse events profile by postoperative rescue analgesia requirement (brackets 
contain column percentages unless otherwise indicated) 
 
 Rescue analgesia consumption P value 
 Yes No  
    
Nausea 
  
  0.003 
Yes 35   (44.3) 11   (19.6) 
 
No 44   (55.7) 45   (80.4) 
 
Vomiting   0.73 
Yes   2     (2.5)   2     (3.6)  
No 77   (97.5) 54   (96.4)  
Stomach pain   0.13 
Yes 18   (22.8)   7   (12.5)  
No 61   (77.2) 49   (87.5)  
Diarrhoea   0.13 
Yes   6     (7.6)   1     (1.8)  
No 73   (92.4) 55   (98.2)  
    
All combineda 79   (58.5) 56   (41.5)  
    
a Brackets contain row percentages 
 
A significantly greater proportion of participants who consumed rescue analgesic experienced 
nausea within the 48-hour postoperative period than those who did not consume rescue 
analgesic (Table 23). 
 
A subgroup analysis showed that, of the participants who did not consume rescue analgesic 
(n=56), the number and proportion of participants who experienced nausea did not differ 
significantly between the two medication groups (Table 24). 
 
Table 24. Postoperative nausea profile in participants who did not consume rescue analgesic 
by group (brackets contain column percentages unless otherwise indicated) 
 
 Group P value 
 Etoricoxib SR ibuprofen  




Yes   6   (22.2)   5   (17.2) 
 
No 21   (77.8) 24   (82.8) 
 





 Postoperative recovery profile 
 
An analysis was conducted to understand specific facets of participants’ postoperative recovery 
during the 48-hour postoperative follow-up period (Table 25). 
 
Table 25. Postoperative recovery by group (brackets contain column percentages unless 
otherwise indicated) 
 
 Group Both combined P value 
 Etoricoxib SR ibuprofen   
     
Sufficient pain relief with 
prescribed analgesia 
   0.10 
No   1      (1.5)     5      (7.4)       6      (4.4)  
Yes 66    (98.5)   63    (92.6)   129    (95.6)  
Overall pain rating    0.60 
Excruciating pain/agony   1      (1.5)    0      (0.0)       1      (0.7)  
Severe   5      (7.5)    6      (8.8)     11      (8.1)  
Moderate 28    (41.8)  34    (50.0)     62    (45.9)  
Mild 27    (40.3)  25    (36.8)     52    (38.5)  
No pain   6      (9.0)    3      (4.4)       9      (6.7)  
Extra analgesia taken other 
than those prescribed 
    
No 67  (100.0)  68  (100.0)   135  (100.0)  
Yes   0      (0.0)    0      (0.0)       0      (0.0)  
Medical GP review required    0.31 
No 66    (98.5)  68  (100.0)   134    (99.3)  
Yes   1      (1.5)    0      (0.0)       1      (0.7)  
Socket irrigation and 
dressing required 
    
No 67  (100.0)  68  (100.0)   135  (100.0)  
     
 
Almost all participants in both groups reported the analgesic regimen provided sufficient pain 
relief during the follow-up period. None of the participants resorted to extra analgesia other 
than those prescribed. 
 
With the verbal rating scale for global postoperative pain, only one participant in the etoricoxib 
group rated ‘excruciating pain and agony’. Just under half of the participants rated ‘moderate 




difference between the two groups in the participants’ overall impression of pain during the 
first 48 hours postoperatively (p=0.60). 
 
Only one participant in the etoricoxib group required a medical GP review for discomfort or 
pain during the follow-up period. Interestingly, this participant rated the overall pain as mild. 





 Ancillary analyses 
 
Further analysis was undertaken to determine whether differences existed in participants who 
also had maxillary third molars removed for the following parameters: overall postoperative 
pain; facial swelling; maximum mouth opening; rescue analgesia requirement; and mean 
OHIP-14 score (Table 26). 
 
Table 26. Postoperative outcomes at 48 h in participants who had at least one maxillary third 
molar extraction in addition to bilateral mandibular third molar extraction, both 
groups combined (brackets contain standard deviations unless otherwise indicated) 
 
 Surgical removal 
of 38 and 48 only 
(n = 45) 
Surgical removal of at least 
one maxillary third molar 
along with 38 and 48 
(n = 90) 
P value 
    
Severe overall postoperative 
paina 
  0.20 
No      39    (86.7)           84    (93.3)  
Yes        6    (13.3)             6      (6.7)  
Mean facial swellingb      17.1   (9.4)           14.7 (10.6) 0.20 
Mean maximum mouth 
openingc 
     31.8   (9.8)           32.7   (8.8) 0.60 
Time taken to rescue 
analgesia requirementd 
       5.6   (4.6)             5.0   (2.9) 0.54 
Total number of rescue 
analgesics consumede 
       3.3   (3.0)             4.2   (4.5) 0.18 
Mean OHIP-14 (48 h)      16.3   (8.6)           15.4   (9.4) 0.57 
    
a Severe or excruciating pain and agony; brackets contain column percentages 
b Volumetric difference (0-48 h) measured in cubic centimetres 
c Interincisal distance measured at maximum mouth opening in millimetres 
d Measured in hours 
e Total number of tablets of codeine phosphate (each tablet is codeine phosphate 30mg) 
 
The majority of participants who had at least one maxillary third molar removed at the time of 
mandibular third molar surgery did not report severe overall postoperative pain (93.3%). This 
was similar to those who had only mandibular third molars removed (86.7%). The mean 
elapsed time from completion of surgery to the consumption of first rescue analgesia and the 




Less postoperative facial swelling (by a mean 2.4cm3) was observed among those who had 
maxillary third molars and their mouth opening was slightly better than those who only had 
mandibular third molars removed. A similar finding was seen with the mean postoperative 
OHIP-14 score. However, the groups did not differ significantly in any of these parameters. 
 
These findings suggest that additional removal of maxillary third molars did not worsen 





Table 27 summarises the effect of primary closure of at least one mandibular third molar socket 
on various postoperative parameters. 
 
Table 27. Postoperative outcomes at 48 h in participants with primary closure of at least one 
mandibular third molar socket, both groups combined (brackets contain standard 
deviations unless otherwise indicated) 
 
 Partial closure of 
mandibular third 
molar sockets 
(n = 95) 
Primary closure of at 
least one mandibular 
third molar socket 
(n = 40) 
P value 
    
Severe overall postoperative 
paina 
  0.30 
No    85    (89.5)      38    (95.0)  
Yes    10    (10.5)        2      (5.0)  
    
Mean facial swellingb    15.0 (10.3)      16.8 (10.3) 0.36 
Mean maximum mouth 
openingc 
   32.4   (9.5)      32.4   (8.4) 0.97 
Time taken to rescue 
analgesia requirementd 
     5.1   (3.5)        5.3   (3.6) 0.89 
Total number of rescue 
analgesics consumede 
     4.2   (4.2)        3.4   (3.6) 0.32 
Mean OHIP-14 (48 h)    15.8   (9.0)      15.6   (9.6) 0.91 
Alveolar osteitisf   0.39 
No    83    (87.4)      37    (92.5)  
Yes    12    (12.6)        3      (7.5)  
Infectiong   0.37 
No    93    (97.9)      38    (95.0)  
Yes      2      (2.1)        2      (5.0)  
    
a Severe or excruciating pain and agony; brackets contain column percentages 
b Volumetric difference (0-48 h) measured in cubic centimetres 
c Interincisal distance measured at maximum mouth opening in millimetres 
d Measured in hours 
e Total number of tablets of codeine phosphate (each tablet is codeine phosphate 30mg) 
f Brackets contain column percentages 
g Brackets contain column percentages 
 
Fewer participants in the primary closure group reported severe overall postoperative pain than 




statistically significant. The mean time taken to the intake of first rescue analgesia and the total 
number of rescue analgesic consumption were comparable between the two groups. 
 
Although more facial swelling was observed among those who had primary closure of at least 
one mandibular third molar socket than in those who had partial socket closure, the difference 
was not statistically significant. The maximum mouth opening was the same in both groups 
(32.4mm) and a similar impact on the postoperative quality of life was found. 
 
Analysis was carried out to assess whether participants who had primary closure of the sockets 
had a lower incidence of alveolar osteitis and a higher incidence of postoperative infection than 
those who had partial closure of the sockets. Alveolar osteitis was slightly more prevalent in 
the partial closure group than the primary closure group (12.6% and 7.5%, respectively). The 
opposite was seen for infection, which was slightly more prevalent in the primary closure group 
than the partial closure group (5.0% and 2.1%, respectively). However, the differences were 
not statistically significant.  
 






Table 28 shows the proportion of participants who reported significant residual pain at 2 weeks 
following third molar surgery. Although more participants in the etoricoxib group than the SR 
ibuprofen group had residual postoperative pain, the difference was not statistically significant. 
 
Table 28. Participants with significant residual pain at 2 weeks postoperatively (brackets 
contain column percentages unless otherwise indicated) 
 
 Group Both combined P value 
 Etoricoxib SR ibuprofen   
     
Residual pain    0.68 
No 63  (94.0)  65  (95.6) 128  (94.8)  
Yes   4    (6.0)    3    (4.4)     7    (5.2)  
     
 
Of the seven participants who had residual pain at 2 weeks postoperatively, five had alveolar 
osteitis (P<0.001) (Table 29). 
 
Table 29. Alveolar osteitis in participants with residual pain at 2 weeks postoperatively, both 
groups combined (brackets contain column percentages unless otherwise indicated) 
 
 Alveolar osteitis Both combined P value 
 Yes No   
     
Residual pain    <0.001 
Yes   5  (33.3)     2    (1.7)     7    (5.2)  
No 10  (66.7) 118  (98.3) 128  (94.8)      








The aim of this study was to compare the effect of pre-emptive SR ibuprofen 1.6g and 
etoricoxib 120mg on pain, swelling, trismus, and the quality of life after impacted third molar 
surgery. The pre-emptive efficacy of long-acting etoricoxib and short-acting, conventional 
ibuprofen has been demonstrated in alleviating acute postoperative pain in third molar surgery 
(Cetira Filho et al., 2020). However, there is no study to date that has investigated how the 
long-acting SR ibuprofen compares to etoricoxib when given as a pre-emptive regimen. 
 
This chapter will highlight the strengths and weaknesses of the methods, followed by a 
discussion of the study findings and their implications for clinical practice, along with 
recommendations for future research. 
 
 Appraisal of methods 
 
 Strengths of the study 
 
To the best of the author’s knowledge, the present study is the first randomised control trial to 
compare the efficacy of pre-emptive SR ibuprofen 1.6g and etoricoxib 120mg for pain, 
swelling, trismus, and the quality of life after third molar surgery. The study sample (n=135) 
exceeded the minimum of 128 participants required to detect an anticipated effect size of 0.5 
with 80% power and an α value of 0.05. 
 
The notable strength of the study was its two-arm parallel design and relatively large sample 
size. There were number of trials investigating pre-emptive analgesia using the split-mouth 
design (Albuquerque et al., 2017; Bauer et al., 2013; Costa et al., 2015; Lustenberger et al., 
2011; Rodrigues et al., 2019; Sotto-Maior et al., 2011). Although split-mouth design offers 
efficiency and improves the precision of the treatment effects, its use is inappropriate for 
examining the effects of pre-emptive analgesia because its carry-across effect would bias the 
interventional effects (Hujoel, 1998). A parallel-arm design does not have elements of carry-
across and period effects, and so it was most appropriate for the present study to minimise bias 




Attempts were made to further reduce bias by employing a simple, unrestricted randomisation 
method, strict blinding, and the involvement of a single surgeon. The randomisation sequence 
was computer-generated, which meant the treatment allocation was completely random and 
unpredictable. Moreover, the large sample size of over 100 participants enabled balance in the 
allocation ratio and the baseline characteristics of the participants in the SR ibuprofen and 
etoricoxib groups (Section 5.3.1), meaning that the risk of any unknown confounders 
inadvertently influencing the study outcomes was minimised. Allocation concealment was 
achieved by having an off-site hospital clinical trials pharmacist who retained the 
randomisation sequence and assigned participants to one of the two treatment groups. No 
member of the research team had access to the allocation scheme. Neither the author nor the 
participant knew the treatment allocation, and the blinding remained until the completion of 
the statistical analysis. Moreover, the blinding and concealment process was further 
strengthened by (a) preparing the SR ibuprofen and etoricoxib capsules to appear identical, and 
(b) the use of sealed, opaque brown envelopes, so that the author was not able to decode to 
which treatment group the participant had been assigned. Surgical procedures were 
standardised for all participants by having a single surgeon and the identical perioperative drug 
protocol. Additionally, careful application of the eligibility criteria helped to minimise any 
factors that could have affected on the postoperative outcomes. Particular attention was paid to 
excluding patients: with known psychiatric conditions; taking psychotropic medications; with 
signs and symptoms of local and/or systemic infection; or using any analgesics within 48 hours 
preoperatively. 
 
Another strength of this study was the use of a contactless 3D stereophotogrammetric imaging 
system to objectively measure the extent of postoperative facial swelling. There is no third 
molar clinical trial to date that has implemented a 3D imaging system to quantify the pre-
emptive analgesic effect on facial swelling. Previous studies used the traditional 
anthropometric method, in which several linear measurements were taken from predetermined 
facial landmarks using a ruler. However, such time-consuming two-dimensional measurements 
are not an accurate measure of the true volumetric extent of the swelling in three anatomical 
dimensions. The 3D stereophotogrammetry’s accuracy and three-dimensional spatial analysis 
to sub-millimetre precision make it a favourable anthropometric device in the contemporary 





 Limitations of the study 
 
The study required all participants to record the intensity of their pain 3-hourly during awake 
hours for 48 hours. This was an attempt to capture data that are informative and best represent 
the realistic course of pain response to pre-emptive analgesia in the early postoperative period. 
Accordingly, the data collection relied on participants’ self-reported measurements of pain 
recorded in a take-home diary. Although the use of diaries is common in pain research, its 
limitation lies in poor control over measure completion, assessment environment, and 
‘retrospective’ backfilling (Younger et al., 2009). To gain some degree of standardisation, the 
starting time was specified for each participant before discharge. For example, all participants 
who had surgery commenced at 9 am (that is, the time of initial incision) were to start recording 
pain at noon. To facilitate adherence, the time points were again specified on day 1 and day 2 
(that is, at 9 am, noon, 3 pm, 6 pm, and so forth until going to bed). Further encouragement 
was provided via day 1 postoperative courtesy text messages. High response rates were noted 
at 6 hours, 9 hours, 24 hours, 27 hours, 30 hours, and 48 hours. The missing data within the 
first 6 hours after the surgery could be attributed to the residual effects of sedation and 
postoperative fatigue. The nature of 3-hourly pain recording could also have led to an 
unintentional loss of data at certain time points that conflicted with participants’ busy day 
schedules. Despite the demanding regime of self-reported pain recordings, the overall level of 
adherence was acceptable. Hence, the number of participants recording their pain was adequate 
to maintain statistical power. 
 
That the study sample primarily comprised young adults is evident from the mean age of 22.6 
years. This is no surprise, given that it coincides with the usual timing of third molar eruptions 
(between the ages of 17 and 26 years) and the concomitant rise in prevalence of symptomatic, 
mandibular third molar impactions (Coulthard et al., 2014; Ghaeminia et al., 2016). Having a 
study sample restricted to young adults may be viewed as a limitation as the sample does not 
adequately represent the general population and any inferences made may not necessarily apply 
to the wider population. However, it is this younger age group which generally presents with 
symptoms justifying third molar extractions. This claim is substantiated by many reported third 
molar clinical trials having used a similar age group of participants to the present study 





It might be argued that the study duration was too short to demonstrate the true reflection of 
postoperative pain in response to pre-emptive analgesia. However, clinical trials assessing the 
effect of pre-emptive analgesia in third molar surgery are confronted with a unique 
circumstance in which participants are exposed to higher likelihood of developing alveolar 
osteitis as the duration of the study lengthens. Alveolar osteitis is a relatively common 
postoperative complication of third molar surgery, with a reported incidence ranging from 7.4% 
to 12.7% (Chuang et al., 2007; Haug et al., 2005). It is characterised by severe pain that 
typically occurs around 3 days postoperatively and may persist for up to 2 weeks (Daly et al., 
2012). Extending the duration of a study means that the likelihood of encountering alveolar 
osteitis is greater. If this complication were to occur, acute postoperative pain would be further 
exacerbated, thereby introducing a new source of peripheral and central sensitisation that can 
contribute to prolonged pain independent of any effects imparted by pre-emptive analgesia. In 
essence, the presence of alveolar osteitis would confound the true effects of pre-emptive 
analgesia in reducing the intensity of acute pain and possibly, the incidence of persistent pain. 
Furthermore, longer studies encounter poorer participant adherence (Merry et al., 2010). 
Considering these issues, the present study’s follow-up period of 48 hours was justifiable. As 
per the School of Dentistry’s postoperative review protocol, participants were reviewed at 2 
weeks. Although not part of this study’s protocol, the number of participants with residual pain 
at this appointment was recorded as supplementary information. 
 
Just under 50% of participants from each medication group experienced moderately intense 
third molar pain while less than 10% experienced severe pain at some point in the 4 weeks 
preceding surgery (Section 5.3.1, Table 8). Preoperative pain is known to worsen the 
postoperative pain (Dahl & Kehlet, 2011), which indicates that the presence of various degrees 
of preoperative pain could have been a confounder influencing the study outcomes. However, 
the mean VAS score taken immediately before the surgery was 7mm for the etoricoxib group 
and 6mm for the SR ibuprofen group (Section 5.4.1, Table 11). Such scores are considered to 
be of mild intensity (Yong & Coulthard, 2010) and given that they were similar in both 
medication groups, the outcomes of the study were unlikely to have been adversely affected. 
 
Finally, the study included the preoperative administration of dexamethasone. Since 
corticosteroids are well-established agents in decreasing swelling (Almeida et al., 2019; Dan 




emptive NSAIDs and facial swelling. However, its use was justifiable because preoperative 
administration of corticosteroids is routinely used in various oral and maxillofacial surgical 
procedures. Omitting this drug would subject participants to unnecessary discomfort and raise 
ethical concerns. Moreover, the author was attempting to replicate a realistic surgical model by 
including dexamethasone to the perioperative protocol, so that the study findings would be 
more meaningful to practising clinicians. 
 
 Research questions 
 
 How did pre-emptive administration of SR ibuprofen 1.6g and etoricoxib 120mg 
compare in the level of postoperative pain following third molar surgery? 
 
There was no statistically significant difference between the SR ibuprofen and etoricoxib 
groups in the level of postoperative pain. However, there was a slightly higher pain level in the 
SR ibuprofen group than the etoricoxib group throughout the study period. The only published 
clinical trial of a similar nature is by Albuquerque et al. (2017), who compared the pre-emptive 
efficacy of etoricoxib 120mg with conventional ibuprofen 400mg and placebo in respect of 
postoperative third molar outcomes. Their findings were similar to the present study in the 
sense that, throughout the 7-day study duration, the VAS scores were consistently higher for 
participants who received ibuprofen than those who took etoricoxib. The peak pain level was 
observed at 2 hours postoperatively in the placebo group (63; SD 29mm), whereas pre-emptive 
administration of etoricoxib (30; SD 23mm) or conventional ibuprofen (39; SD 24mm) delayed 
this to 4 hours postoperatively. Consistent with the clinical trial by Costa et al. (2015), the 
etoricoxib group in the present study reached its peak pain (33; SD 23mm) at 6 hours, while 
the SR ibuprofen group took longer, reaching its maximum pain (35; SD 26mm) at 9 hours. 
Despite this delay being observed in the ibuprofen group, the actual peak VAS scores between 
the two medication groups were comparable and the difference is unlikely to be clinically 
meaningful. It is noteworthy that, at the 9-hour time point, the greatest pain intensity difference 
between the two groups was observed (Section 5.4.1, Figure 10); that is, while the pain was at 
its worst in the SR ibuprofen group, the opposite was seen in the etoricoxib group. It is also 
noteworthy that SR ibuprofen, relative to its conventional counterpart in the Albuquerque et al. 
study, delayed the pain peak by 5 hours. This may be explained by the postoperative temporal 




pharmacokinetics of conventional and SR ibuprofen. Gordon et al. (2002) showed the 
expression of inducible COX-2 activity occurring 2 to 3 hours postoperatively with a 
concurrent elevation in the PGE2 level in the third molar surgical site and the onset of pain. 
This finding is further corroborated by Renner et al. (2012), who demonstrated that oral 
administration of etoricoxib 2 hours before hip replacement suppressed both PGE2 levels in the 
surgical site and interleukin-6 in the plasma. The reduction in the inflammatory mediators was 
associated with a lower postoperative opioid demand and better satisfaction with pain control. 
In the Albuquerque et al. study, conventional ibuprofen was administered orally 1 hour 
preoperatively. Considering ibuprofen’s rapid absorption and short half-life, its decreasing 
serum concentration would have coincided with the elevation of PGE2 level and therefore, 
resulted in an earlier onset of peak pain. By contrast, SR ibuprofen takes about 3 hours to reach 
its peak serum concentration, by which time the increasing PGE2 level would have been 
intercepted by the COX-inhibiting action of SR ibuprofen at its therapeutic concentration, thus 
delaying the time taken to reach its maximal pain level. 
 
The present study showed no intergroup difference in the rescue analgesia requirement. Just 
over half of the participants in each medication group resorted to rescue analgesia (Section 
5.4.2, Table 12). Participants who received SR ibuprofen took more codeine than those who 
received etoricoxib, but the difference was just one tablet of codeine (that is, 30mg). Consistent 
with the findings of Albuquerque et al. (2017), there was no clinically significant difference 
between the two groups in the current study for the time taken to seek first rescue analgesia 
following surgery (Section 5.4.2, Table 12). A similar finding was reported in the clinical trial 
by Yong and Coulthard (2010), where participants in the SR ibuprofen group took a mean of 
3.2 hours to consume the first rescue analgesic while those in the conventional ibuprofen group 
took 2.7 hours. Interestingly, the participants in the present study took a much longer time 
before resorting to rescue analgesia (approximately 5 hours) than reported by Albuquerque et 
al. and Yong and Coulthard (ranging from 2 to 3 hours). Although the consumption of rescue 
analgesic is indeed dependent on the intensity of the pain (Albuquerque et al., 2017; Costa et 
al., 2015), the demand for rescue analgesia does not always reflect poor pain control. Patients 
may elect to take extra analgesics to reduce pain-related anxiety, as a prophylactic strategy to 
avoid aggravating pain with increased activity, and/or to improve sleep (Dworkin et al., 2005). 




could exist between the current study and those reported earlier in the time taken by study 
participants to resort to rescue analgesia following third molar surgery. 
 
The widely used definition of chronic postsurgical pain (CPSP) is persistent pain of at least 2 
months’ duration that develops after surgery, with no definable organic cause (Macrae, 2008). 
The nature of central sensitisation arising from acute postoperative pain is similar to that seen 
in CPSP, and it is suggested that the intensity of acute pain may influence its transition to 
chronic pain (Clarke et al., 2012; Dahl & Kehlet, 2011). Moreover, because persistent 
inflammation is also thought to contribute to the pathophysiology of CPSP, it has been 
hypothesised that pre-emptive analgesia may be able to prevent persistent pain after surgery 
(Dahl & Møiniche, 2004). Thus, many general surgical and orthopaedic clinical trials assess 
chronic pain and its characteristics in the very late postoperative period (for example, at least 
3 months postoperatively) (Buvanendran et al., 2010; Dullenkopf et al., 2009; Şen et al., 2009). 
However, data on the effectiveness of pre-emptive analgesia in reducing the incidence of CPSP 
after third molar surgery is scarce. Review of the relevant literature indicates two underlying 
reasons for this. First, it may be that misconception about pre-emptive analgesia has 
inadvertently led many investigators to remain unaware of CPSP, as seen by a heavy emphasis 
on the acute postoperative pain but no acknowledgement of the aspect of chronic pain in the 
third molar literature (Cetira Filho et al., 2020). The second reason may be ascribed to the 
postoperative nature of third molar surgery. Patients experience short-term acute pain that 
peaks between 48-72 hours and improves by day 7 after the surgery (Coulthard et al., 2014). 
Accordingly, many third molar clinical trials concerned with postoperative pain are of short 
duration, ranging from 6 hours to a maximum of 7 days. The incidence of chronic pain after 
third molar surgery is low (0.4% to 2.2%) (Berge, 2002), whereas up to one in ten patients who 
have abdominal, thoracic, or orthopaedic surgery reportedly experience severe persistent pain 
(Kehlet & Rathmell, 2010). Taking these observations together, it could be argued that many 
investigators may have been disinclined, or found it irrelevant, to collect long-term data on 
persistent pain after third molar surgery, simply because of its uncommon occurrence. 
 
The anaesthesiology literature presents a conceptual transition from pre-emptive to preventive 
analgesia (Katz et al., 2011). Although both strategies have a unifying goal to reduce the level 
of acute pain and to prevent the development of chronic pain, the preventive approach is exempt 




duration of the intervention (Dahl & Kehlet, 2011; Katz et al., 2011; Kissin, 2011). Curiously, 
this concept is yet to be universally accepted in the surgical field, including oral and 
maxillofacial surgery; the use of the term “pre-emptive analgesia” remains prevalent in the 
surgical literature. 
 
 How did pre-emptive administration of SR ibuprofen 1.6g and etoricoxib 120mg 
compare in their effects on swelling following third molar surgery? 
 
There was no intergroup difference in facial swelling in the present study (Section 5.4.3, Table 
13). There is a paucity of data on the effectiveness of pre-emptive use of NSAIDs in alleviating 
postoperative facial oedema. Moreover, the limited available evidence presents conflicting 
findings (Cetira Filho et al., 2020), making postoperative swelling a difficult parameter to 
understand. Albuquerque et al. (2017) found no difference in the cumulative effect of five 
different facial measurements between the pre-emptive etoricoxib 120mg, conventional 
ibuprofen 400mg, and placebo groups during the 7-day postoperative period. Similarly, Costa 
et al. (2015) demonstrated no difference in facial swelling between those who received pre-
emptive etoricoxib120mg and those receiving a placebo. Interestingly, clinical trials 
investigating the differences between pre-emptive etoricoxib (90mg and 120mg) and 
dexamethasone 4mg showed comparable facial volumetric changes, suggesting that etoricoxib 
is just as efficacious as dexamethasone for controlling oedema after third molar surgery 
(Rodrigues et al., 2019; Sotto-Maior et al., 2011). Direct comparisons are hampered by the 
heterogeneity of reported methods of measuring facial swelling (Coulthard et al., 2014). These 
issues also underline a need for further studies to evaluate the pharmacological action of pre-
emptive SR ibuprofen and etoricoxib against inflammatory mediators and how they would 
impact postoperative facial swelling. 
 
 How did pre-emptive administration of SR ibuprofen 1.6g and etoricoxib 120mg 
compare in their effects on trismus following third molar surgery? 
 
The extent of mouth opening was comparable between the two groups in the present study 
(Section 5.4.3, Table 13). Contrary to this, participants who received etoricoxib in the 
Albuquerque et al. clinical trial had better mouth opening (39.2; SD 8.4mm) than those who 




The difference seen in the current study could be attributed to the longer duration of action of 
SR ibuprofen than its conventional formulation, and its implications for pain. The sustained 
anti-inflammatory activity may have suppressed the prostaglandin level from rising over time, 
whereas the action of conventional ibuprofen may have dissipated within the early 
postoperative period. The latter may have exacerbated pain-mediated modulation of 
masticatory motor function in the conventional ibuprofen group, thus worsening the degree of 
trismus, as reflected by their significantly higher accumulated pain level than the etoricoxib 
group in the Albuquerque et al. study. This hypothesis is reinforced by findings from the studies 
examining the pre-emptive effectiveness of etoricoxib 90mg and 120mg against 
dexamethasone 4mg on postoperative trismus (Rodrigues et al., 2019; Sotto-Maior et al., 2011). 
The half-life of etoricoxib is 22 hours (Agrawal, Porras, et al., 2003), while that of 
dexamethasone is at least 36 hours (Becker, 2013). The long half-lives of these agents, in 
conjunction with comparable postoperative pain levels, may partly explain the similarity in 
mouth opening between the pre-emptive etoricoxib and dexamethasone groups (Rodrigues et 
al., 2019; Sotto-Maior et al., 2011). Oedema in masticatory muscles has been suggested to limit 
jaw movement (Balakrishnan et al., 2017; Ernberg et al., 2007; Hupp et al., 2018). Interestingly, 
there was no difference in facial swelling between the etoricoxib and ibuprofen groups in the 
Albuquerque et al. study, yet a significant difference was found in mouth opening. On the 
contrary, the present study demonstrated no statistically significant differences in postoperative 
pain, swelling, or mouth opening. 
 
 How did pre-emptive administration of SR ibuprofen 1.6g and etoricoxib 120mg 
compare in their effects on patients’ self-reported quality of life following third molar 
surgery? 
 
Oral-health-related quality of life worsened to a moderate degree in both medication groups 
after third molar surgery (Section 5.4.5, Table 20). Although the etoricoxib group reported a 
slightly better quality of life than the SR ibuprofen group, the difference was not statistically 
significant. Interestingly, an almost significant difference (p=0.05) was observed whereby a 
smaller proportion of participants in the etoricoxib group reported a severe impact of third 
molar surgery on their quality of life. The OHIP-14 subscale scores showed the highest increase 
in the domain of physical pain in both medication groups, followed by physical disability and 




irrespective of the type of pre-emptive analgesia—had its greatest impact in the form of painful 
aching in the mouth, difficulty in eating, unsatisfactory diet with interruptions in meals, and 
difficulty pronouncing words. This finding is consistent with those of a clinical trial by Majid 
and Al-Mashhadani (2014), who found that eating was the most impaired domain despite 
perioperative administration of bromelain and diclofenac. Moreover, postoperative pain is 
frequently cited as the primary factor responsible for the sudden decline in the life quality after 
third molar surgery (Duarte-Rodrigues et al., 2018; Mcgrath et al., 2003; van Wijk et al., 2009). 
Pain can compromise physical functioning and for some, the anticipation of pain or worsening 
of pain with movement can result in a voluntary restriction of activity (Dworkin et al., 2005; 
Younger et al., 2009). In third molar surgery, this is supported by the observation that, as the 
proportion of patients with severe postoperative pain declined, a trend was seen towards 
improvement in oral function, such as talking and eating normally (Shugars et al., 2006; White 
et al., 2003). From the psychosocial standpoint, participants in the etoricoxib and SR ibuprofen 
groups experienced the greatest adverse impact in the social disability subscale (that is, “being 
irritable with other people” and “having difficulty doing usual jobs”). Although the score was 
slightly higher for those who received SR ibuprofen, further investigation is required of how 
the different pre-emptive analgesics compare in their influence on the postoperative 
psychological, emotional, and social characteristics of individuals and how these psychosocial 
variables are associated with clinical outcomes and the postoperative recovery profile. 
 
It is noteworthy that the OHIP has more ‘global’ relevance, with the questionnaire 
encompassing impacts ascribed to a diverse range of oral conditions, instead of focusing on a 
specific condition. While the OHIP captures a good overall outcome, it may discount small, 
yet clinically significant differences which are intrinsic to a particular oral condition (Shugars 
et al., 2006). A condition-specific health-related quality of life instrument (the HRQOL) is 
tailored to the transient postoperative sequelae of third molar surgery (Shugars et al., 1996). 
The HRQOL pertains to four specific categories of dental outcome: pain (the severity, duration, 
and character); oral function (the ability to chew, speak, and open mouth wide); lifestyle (the 
ability to continue routine activities, such as attending school/work, engaging in social 
life/leisure activities, and sleeping); and other symptoms specific to third molar surgery 
(swelling, bruising, bleeding, bad taste/breath, food impaction, lip numbness, and nausea) 
(Shugars et al., 1996). The condition-specific HRQOL and OHIP-14 may appear somewhat 




dimensions, such as “opening your mouth wide” and “swelling of your cheeks”, but disregards 
the surgery-specific psychological domains and social disability that are addressed by the 
OHIP-14 (Shugars et al., 2006; White et al., 2003). Accordingly, using both complementary 
instruments would have been more informative in comparing the pre-emptive analgesic 
benefits of SR ibuprofen and etoricoxib on the quality of life. However, this needs to be 
balanced against the extended burden of documentation load on participants which may 
adversely affect adherence to study reporting protocols. 
 
 How did pre-emptive administration of SR ibuprofen 1.6g and etoricoxib 120mg 
compare on the adverse events (side-effects)? 
 
Supplementary data were collected on adverse events (nausea, vomiting, stomach pain, 
diarrhoea, and any other side-effects experienced) associated with the single pre-emptive dose 
of the study medications. Adverse events were similar between SR ibuprofen and etoricoxib 
during the 48-hour study duration. Consistent with previously reported data (Daniels et al., 
2011; Malmstrom et al., 2005), nausea was the most prevalent adverse event, affecting 
approximately one-third of participants in the present study (Section 5.4.6, Table 22). It is 
somewhat surprising that a substantial proportion of participants reported nausea, given that: 
(1) systematic reviews of single-dose trials demonstrate good tolerability profiles for etoricoxib 
and ibuprofen (Derry et al., 2009; Moore et al., 2015a); and (2) dexamethasone is 
coincidentally indicated for prophylaxis of postoperative nausea and vomiting (Becker, 2013). 
It is feasible, then, to consider the rescue analgesic being the culprit for the relatively high 
frequency of nausea. This speculation is supported by the fact that over half of the participants 
consumed codeine, an opioid with well-documented side-effects of nausea and vomiting 
(Smith, 2009). Furthermore, clinical trials investigating the analgesic effects of ibuprofen, 
etoricoxib, paracetamol/codeine, and paracetamol/oxycodone identified the opioid treatments 
to be associated with a significantly higher incidence of nausea (Daniels et al., 2011; 
Malmstrom et al., 2005). Further analysis in the present study showed that a significantly 
greater proportion of participants who consumed rescue analgesic experienced nausea during 
the 48-hour postoperative period (Section 5.4.6, Table 23). Of the 56 who did not consume 
rescue analgesic, the incidence of nausea was similar in the two medication groups (Section 





Stomach pain was another frequently reported adverse event. Gastrointestinal safety of single-
dose etoricoxib and ibuprofen is endorsed by systematic reviews (Clarke et al., 2014; Derry et 
al., 2009), yet approximately 20% of participants reported stomach pain in the present study. 
It is possible that regular consumption of ibuprofen, as per postoperative analgesic protocol, 
may have been a contributing factor. The recommendation is to take ibuprofen with food 
because it is presumed that food or milk provides some gastro-protective effects against 
NSAIDs (Rainsford & Bjarnason, 2012). Considering that many patients have difficulty in 
eating following third molar surgery (Shugars et al., 2006), it is sensible to theorise that some 
participants could have taken ibuprofen on a relatively empty stomach, thereby predisposing 
them to epigastric pain/discomfort. 
 
 Clinical implications of the study findings 
  
The present study demonstrated an equivalent performance of pre-emptive SR ibuprofen and 
etoricoxib in acute postoperative sequelae following third molar surgery. Globally, etoricoxib 
is more expensive than the conventional NSAIDs. Hence, pre-emptive administration of the 
inexpensive SR ibuprofen could be used as a suitable and economical alternative to the more 
expensive etoricoxib in third molar surgery. SR ibuprofen and etoricoxib had comparable 
adverse events profiles, suggesting that healthy individuals with no contraindications for 
NSAID use will tolerate both medications equally if administered as a single pre-emptive 
regimen. 
  
  Generalisability of findings to other surgical fields 
 
It must be emphasised that any pain-related findings from studies investigating the effects of 
pre-emptive analgesia may differ depending on the nature of, and the postoperative course 
specific to a given surgical procedure (Ochroch et al., 2003). Hence, generalisation of the 
present study findings (utilising a third molar impaction model) to certain operations, such as 
orthopaedic and thoracic procedures, may be inappropriate because those entail a higher degree 
of postoperative pain of longer duration and which is more likely to establish chronic pain 
(Kehlet & Rathmell, 2010; Ochroch et al., 2003). However, it is a reasonable expectation for 
the findings of the current study to be applicable to other surgical fields of dentistry, such as 




surgical endodontics. Most of these procedures have similitudes with third molar surgery, given 
that they may require a local flap elevation and ostectomy. Accordingly, the level of 
postoperative pain associated with these dental procedures is likely to be similar to that which 
results from third molar extractions, thereby supporting the pre-emptive use of either SR 
ibuprofen or etoricoxib in those clinical situations. Pereira et al. (2020) reported pre-emptive 
ibuprofen 600mg was effective in reducing pain following implant surgery. Steffens et al. 
(2011), in their periodontal open-flap debridement study, demonstrated that a single pre-
emptive dose of etoricoxib 120mg was just as effective as celecoxib 200mg given pre- and 
postoperatively. 
 
 Future directions 
 
Since pain is intimately linked to the psychosocial characteristics of an individual, assessment 
for any perioperative changes in the psychosocial factors has been recommended to augment 
the current understanding of the impact of pre-emptive analgesia on postoperative pain (Dahl 
& Kehlet, 2011; Katz et al., 2011). Despite this recommendation, publications on pre-emptive 
analgesia in third molar surgery show a dearth of information on the impact of psychological, 
emotional, and social functioning (and aspects of personality) on the level of acute pain and 
the postoperative recovery process. Additionally, there is no specific instrument designed to 
appropriately characterise the emotional and psychological states of individuals and their acute 
postoperative pain experienced in the context of pre-emptive analgesia. Therefore, the focus 
should be to develop a novel instrument specific to third molar surgery that will facilitate the 
identification of any risk factors for heightened acute postoperative pain, delayed recovery, and 
chronic pain development. 
 
Clinical trials investigating the temporal relationship between the systemic and local expression 
of inflammatory markers (following the perioperative administration of NSAIDs) and 
postoperative sequelae are necessary to better appreciate the pharmacological mechanisms 
underlying the pre-emptive roles of SR ibuprofen and etoricoxib in pain, swelling, and trismus. 
 
Lastly, future studies should use 3D stereophotogrammetry to assess facial swelling. 3D 
imaging systems enable accurate quantification of facial volumetric changes which is 




sub-millimetre level facilitates detailed volumetric comparison of the effects of different 
perioperative agents. Its routine use would facilitate the standardisation of the measurement 
approach across future clinical trials, which will further assist in comparing data from different 
studies. It is important to highlight that data is lacking on what constitutes a clinically 
significant volumetric change after third molar extractions. Additionally, there is no evidence 
on how a patient’s perception of facial swelling and that of a clinician associate with an 
objectively quantified postoperative volumetric change. Qualitative studies would be of 
enormous value in determining such threshold that is not only clinically significant, but also 







There were no significant differences between the pre-emptive SR ibuprofen 1.6g and 
etoricoxib 120mg in pain, swelling, trismus, and the quality of life in the early postoperative 
period after third molar surgery. 
 
Pre-emptive administration of the more economical SR ibuprofen could be used as a suitable 
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PARTICIPANT INFORMATION SHEET 
 
Preoperative effects of anti-inflammatory drugs on pain and inflammation 
following wisdom teeth removal 
 
Locality: Department of Oral Diagnostic and Surgical Sciences, School of Dentistry 
Principal Researcher: YJ Jessica Lee (Oral Surgery Doctorate Candidate) 
Primary Supervisor: Mr Harsha De Silva (Senior Lecturer in Oral & Maxillofacial Surgery) 
Contact number: (03) 479 7023 or 021 082 94037 
Ethics Committee Ref: 18/STH/139 
 
We invite you to take part in a clinical study on the effects of preoperative anti-inflammatory 
drugs on pain and inflammation following wisdom teeth surgery. Whether or not you take part 
is your choice. If you don’t want to take part, you don’t have to give a reason, and it won’t 
affect the care you receive. If you do want to take part now, but change your mind later, you 
can pull out of the study at any time.   
 
This Participant Information Sheet will help you decide if you’d like to take part. It sets out 
why we are doing the study, what your participation would involve, what the benefits and risks 
to you might be, and what would happen after the study ends. We will go through this 
information with you and answer any questions you may have. You do not have to decide today 
whether or not you will participate in this study. Before you decide you may want to talk about 
the study with other people, such as family, whānau, friends, or healthcare providers. Feel free 
to do this. 
 
If you agree to take part in this study, you will be asked to sign the Consent Form on the last 
page of this document. You will be given a copy of both the Participant Information Sheet and 
the Consent Form to keep. 
 
This document is 5 pages long, including the Consent Form. Please make sure you have read 
and understood all the pages. 
 
What is the aim of the research project? 
This project is being undertaken as part of an Oral Surgery Doctorate degree at the University 
of Otago. The aim is to compare the preoperative effectiveness of two different types of anti-
inflammatory painkillers on pain, swelling, and mouth opening after wisdom teeth surgery. The 
medications involved in this project are etoricoxib (Arcoxia) 120mg and sustained-release 
ibuprofen 1.6g, two commonly used painkillers. Arcoxia is shown to be effective when given 
before bone and gall bladder operations but not much is known about its benefit in wisdom 
teeth surgery. Participants will be randomly assigned to a group. To help minimise bias, neither 





Who pays for the study? 
This study is funded by the Sir John Walsh Research Institute Doctor of Clinical Dentistry 
Research Grant. 
 
Participants will bear the cost of surgical treatment according to the fee guidelines of the School 
of Dentistry, University of Otago, and the postoperative medications prescribed, except the 
study medications (Arcoxia, sustained-release ibuprofen) which will be provided free of charge. 
 
Who are we seeking to participate in the project? 
Anyone between 18 and 35 years of age who requires the removal of at least 2 impacted lower 
wisdom teeth are invited to participate. Participants must be healthy with no significant medical 
conditions and must not have any allergic reactions to anaesthetics/sedatives, anti-inflammatory 
painkillers (e.g. Nurofen, Voltaren), and codeine. Female patients who are pregnant or 
breastfeeding will not be able to participate. 
 
What will participants be asked to do? 
Should you agree to take part in this project, you will be asked to: 
1. Complete a short questionnaire asking about things such as your age, gender, occupation, 
oral hygiene practice, past or present pain associated with your wisdom teeth, and 
whether you experience anxiety when receiving dental treatment . 
2. Attend your surgical appointment. You will need to take a medication given to you 2 
hours before the surgery. Before the wisdom teeth removal, your facial dimension will 
be assessed by a 3D scanner and your mouth opening will be measured. 
3. Fill in your pain diary. This involves scoring your pain level every 3 hours (while awake) 
for the first 2 days after the surgery. You will also need to answer questions relating to 
the use of painkillers and any side-effects encountered. Each occasion will take only a 
moment of your time. 
4. Attend a review appointment with Jessica Lee 2 days after the surgery, at which time 
she will: 
a. Assess the extent of facial swelling and mouth opening; 
b. Collect your pain diary; and 
c. Ask you to complete a short questionnaire about your experience of pain 
following the wisdom teeth surgery 
 
Benefits and risks of participating in this study 
Surgical removal of wisdom teeth is a common procedure provided at the School of Dentistry, 
University of Otago. The medications provided to you before your wisdom teeth surgery are 
known to have a good effect in controlling postoperative pain. The effective dose of the 
medication will remain the same; we will be giving the medication before the surgery rather 
than after the surgery. Like all anti-inflammatory painkillers, the side-effects of ibuprofen and 
Arcoxia may include stomach pain in some people. Despite this, ibuprofen and Arcoxia are 
commonly prescribed following wisdom teeth surgery. Therefore, there are no increased risks 
by participating in this study. It’s important that you DON’T combine two types of anti-
inflammatory painkillers as this could increase the risk of postoperative bleeding. 
 
We will give you a free bottle of antibacterial mouthwash and a prescription for painkillers. 
These painkillers are no different to those given to patients undergoing wisdom teeth surgery 





If you believe that the painkillers provided to you by the School of Dentistry are making you 
feel unwell, then you are advised to stop taking those tablets and contact your medical doctor 
for an alternative painkiller. 
 
What if something goes wrong? 
If you were injured in this study, which is unlikely, you would be eligible for compensation 
from ACC just as you would be if you were injured in an accident at work or at home. You will 
have to lodge a claim with ACC, which may take some time to assess. If your claim is accepted, 
you will receive funding to assist in your recovery. 
 
If you have private health or life insurance, you may wish to check with your insurer that taking 
part in this study won’t affect your cover. 
 
What about anonymity and confidentiality? 
Your participation in this study is strictly confidential. Any personal information such as your 
name, age, gender, and contact details will remain anonymous. The information collected from 
you will be de-identified and used only by the researchers involved in this project. The de-
identified information (study data) will be stored securely at the University of Otago for a period 
of 10 years, after which time it will be destroyed. 
 
The results of this study will be written up in the form of a thesis and may later be summarised 
and published in a dental journal in order that other dentists and their patients may benefit. 
Nothing that could identify you will be used in anything we publish. 
 
If I agree to participate, can I withdraw later? 
Your participation in this research is entirely voluntary and you can withdraw at any time with 
no disadvantage to you. To participate you will need to fill in the accompanying consent form. 
You are welcome to request a copy of the final results of this research project if you desire. You 
have the right to access your personal data. 
 
What if I have any questions about the research project? 
If you require additional information, please do not hesitate to contact Jessica Lee or Mr Harsha 
De Silva on (03) 479 7023 or 021 082 94037 during business hours. 
 
What if I have any problems or require additional pain relief following my wisdom teeth 
surgery? 
If you need to contact the oral surgery team following your wisdom teeth surgery, you may do 
so during business hours on (03) 479 7023 or 021 082 94037. For after-hours emergency, you 
may contact Dunedin Public Hospital on (03) 474 0999 and ask to be put through to the on-call 
Dental House Surgeon. 
 
For Māori health support, please contact Professor John Broughton, Associate Dean (Māori), 
Faculty of Dentistry, on (03) 479 7639. 
 








CONSENT FORM FOR PARTICIPANTS 
 
Preoperative effects of anti-inflammatory drugs on pain and inflammation following 
wisdom teeth removal 
 






















Oral Surgery research project 
Department of Oral Diagnostic and Surgical Sciences, School of Dentistry, University of Otago 
 
Principal Researcher: YJ Jessica Lee (Oral Surgery Doctorate Candidate) 
Primary Supervisor: Mr Harsha De Silva (Senior Lecturer in Oral & Maxillofacial Surgery) 
 
Thank you for taking the time to fill in this questionnaire. 
You are kindly requested to complete this questionnaire during your wisdom teeth appointment 
with YJ Jessica Lee. 
 
For information about this research project, please read the form entitled: “Information sheet 
for participants: Preoperative effects of anti-inflammatory drugs on pain and inflammation 
following wisdom teeth removal.” 
 
All personal information collected will remain strictly confidential. 














Question 3   
Which ethnic groups do you belong to? (please circle all which apply) 
















Others (please state): 
 
Question 4 






























b. If so, how many times have you had pain or discomfort with your wisdom teeth? 
 
 











How would you describe the health of your teeth and mouth?  (please circle) 




How often do you usually brush your teeth?  (please circle) 
 
More than once a day                Once a day 
        
Not every day    Less than once a week    Never   
     
 
Yes No 
Always Often Sometimes Occasionally Never 





Please circle the answer that BEST applies to you during the last 4 weeks. 
 
























Level of Pain before Wisdom Teeth Removal 
 






Place a vertical mark on the line below to indicate your current level of pain. 
     




    
 
  



















The distance between the mesio-incisal edges of the right maxillary and mandibular 















Level of Pain following Wisdom Teeth Removal 
 
During awake hours, please complete every 3 hours for the first 48 hours following your 







Place a vertical mark on the line below to indicate your current level of pain. 
     














The use of pain medication on the day following wisdom teeth removal 
 







1. How long did it take you to the first use of rescue pain relief (codeine phosphate) after your 
wisdom teeth surgery? 
                   hours 
 
 
2. If you have taken rescue pain relief (codeine phosphate), how may tablets did you take on 
the day of surgery? 
 












The use of pain medication 1 day following wisdom teeth removal 
 








If you have taken rescue pain relief (codeine phosphate), how may tablets did you 
take on the 1st day following surgery? 
 
 












The use of pain medication 2 days following wisdom teeth removal 
 
 








If you have taken rescue pain relief (codeine phosphate), how may tablets did you 
take on the 2nd day following surgery? 
 
 















Oral Surgery research project 
Department of Oral Diagnostic and Surgical Sciences, School of Dentistry, University of Otago 
 
Principal Researcher: YJ Jessica Lee (Oral Surgery Doctorate Candidate) 
Primary Supervisor: Mr Harsha De Silva (Senior Lecturer in Oral & Maxillofacial Surgery) 
 
Thank you for taking the time to fill in this questionnaire. 
 
You are kindly requested to complete this questionnaire during your review appointment with 
YJ Jessica Lee two days after surgery. 
 
For information about this research project, please read the form entitled: “Information sheet 
for participants: Preoperative effects of anti-inflammatory drugs on pain and inflammation 
following wisdom teeth removal.” 
 
All personal information collected will remain strictly confidential. 
















Overall, how would you rate your pain following your surgery? 
 
No Pain      Mild Pain      Moderate Pain      Severe pain      Excruciating 
pain & agony 
 
Question 4 




   If yes, please mention the name(s) and duration _______________________ 
 
Question 5 














Please circle the answer that BEST applies to you following your wisdom teeth removal. 
 
Because of trouble with your teeth, mouth or dentures: 
 



















The distance between the mesio-incisal edges of the right maxillary and mandibular 












Side-effects following wisdom teeth removal 
 





Side-effect #1: Nausea (feeling sick) 
 
 
Have you experienced this symptom following your wisdom teeth surgery? 
 
Yes          No 
 
 
If “YES”, please comment below 
 
1. Did you experience this symptom before your wisdom teeth surgery? 
 
Yes          No 
 
2. How often did you experience this symptom after your wisdom teeth surgery? 
 
Never       Hardly ever       Occasionally       Fairly often       Very often 
 
3. How severe was this symptom? 
 
Not applicable          Mild          Moderate          Severe 
 
4. How much did this symptom affect your day? 
 





Side-effect #2: Vomiting 
 
 
Have you experienced this symptom following your wisdom teeth surgery? 
 
Yes          No 
 
 
If “YES”, please comment below 
 
1. Did you experience this symptom before your wisdom teeth surgery? 
 
Yes          No 
 
2. How often did you experience this symptom after your wisdom teeth surgery? 
 
Never       Hardly ever       Occasionally       Fairly often       Very often 
 
3. How severe was this symptom? 
 
Not applicable          Mild          Moderate          Severe 
 
4. How much did this symptom affect your day? 
 




Side-effect #3: Stomach pain 
 
 
Have you experienced this symptom following your wisdom teeth surgery? 
 
Yes          No 
 
 
If “YES”, please comment below 
 
1. Did you experience this symptom before your wisdom teeth surgery? 
 
Yes          No 
 
 
2. How often did you experience this symptom after your wisdom teeth surgery? 
 













3. How severe was this symptom? 
 
Not applicable          Mild          Moderate          Severe 
 
4. How much did this symptom affect your day? 
 
Not at all        A little        Some        A lot 
 
 
Side-effect #4: Diarrhoea 
 
 
Have you experienced this symptom following your wisdom teeth surgery? 
 
Yes          No 
 
 
If “YES”, please comment below 
 
1. Did you experience this symptom before your wisdom teeth surgery? 
 
Yes          No 
 
2. How often did you experience this symptom after your wisdom teeth surgery? 
 
Never       Hardly ever       Occasionally       Fairly often       Very often 
 
3. How severe was this symptom? 
 
Not applicable          Mild          Moderate          Severe 
 
4. How much did this symptom affect your day? 
 




Have you experienced any other symptoms following your wisdom teeth surgery? 












PARTICIPANT CONSENT FOR MEDICAL PHOTOGRAPHY 
 
Preoperative effects of anti-inflammatory drugs on pain and inflammation 
following wisdom teeth removal 
 
Locality: Department of Oral Diagnostic and Surgical Sciences, School of Dentistry 
Principal Researcher: YJ Jessica Lee (Oral Surgery Doctorate Candidate) 
Primary Supervisor: Mr Harsha De Silva (Senior Lecturer in Oral & Maxillofacial Surgery) 
Contact number: (03) 479 7023 or 021 082 94037 
Ethics Committee Ref: 18/STH/139 
 
 
I give consent for medical photographs to be taken of me. 
 
I understand that copies of my photograph may be used for education, publication, and research 
(that is, use in research thesis, scientific presentations and posters, and journal articles). 
 
Allowing my photograph to be used will not involve any additional costs to me. I will not 
receive any compensation. 
 
I understand that I have the right to withdraw consent at any time. However, once the 
article/research is written and published, it will not be possible to withdraw it. 
 
I understand that my personal information (for example, name, date of birth, contact details) 
will not be disclosed, or any information that identifies me as an individual. When the article is 
published or presented, my identity will not be disclosed. 
 
I understand that I will not directly benefit from participating in this clinical trial. The 
information that can be shared with other health care professionals, however, may improve the 
care that is received by others in the future. 
 
 
Name:                                 
 
 
Signature:                                
 
 
Date:                                 
